

1 **Identifying molecular mediators of the relationship between body mass index and**
2 **endometrial cancer risk: a Mendelian randomization analysis**

3
4 Emma Hazelwood^{1,2}, Eleanor Sanderson^{1,2}, Vanessa Y Tan^{1,2}, Katherine S Ruth³, Timothy M Frayling⁴, Niki
5 Dimou⁵, Marc J Gunter⁵, Laure Dossus⁵, Claire Newton⁶, Neil Ryan^{6,7}, Dimitri J Pournaras⁸, Tracy A
6 O'Mara⁹, George Davey Smith^{1,2}, Richard M Martin^{1,2,10}, James Yarmolinsky^{1,2}

7
8 ¹MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK

9 ²Bristol Medical School, University of Bristol, Bristol, UK

10 ³University of Exeter Medical School, University of Exeter, Exeter, UK

11 ⁴Genetics of Complex Traits, College of Medicine and Health, University of Exeter, Exeter, UK

12 ⁵Nutrition and Metabolism Branch, International Agency for Research on Cancer, Lyon, France

13 ⁶Department of Gynecology, St Michaels Hospital University Hospitals Bristol NHS Foundation Trust,
14 Bristol, UK

15 ⁷The Academic Women's Health Unit, Translational Health Sciences, Bristol Medical School, University of
16 Bristol, Bristol, UK

17 ⁸Department of Upper GI and Bariatric/Metabolic Surgery, North Bristol NHS Trust, Southmead Hospital,
18 Bristol, UK

19 ⁹Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute,
20 Brisbane, Queensland, Australia

21 ¹⁰National Institute for Health Research Bristol Biomedical Research Centre, University of Bristol,
22 University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK

23

24 **Corresponding author:**

25 James Yarmolinsky, PhD
26 MRC Integrative Epidemiology Unit
27 Population Health Sciences
28 Bristol Medical School
29 University of Bristol
30 Bristol, UK
31 james.yarmolinsky@bristol.ac.uk

32 **Abstract**

33 Background: Endometrial cancer is the most common gynaecological cancer in high-income countries.

34 Elevated body mass index (BMI) is an established modifiable risk factor for this condition and is

35 estimated to confer a larger effect on endometrial cancer risk than any other cancer site. However, the

36 molecular mechanisms underpinning this association remain unclear. We used Mendelian

37 randomization (MR) to evaluate the causal role of 14 molecular risk factors (hormonal, metabolic, and

38 inflammatory markers) in endometrial cancer risk. We then evaluated and quantified the potential

39 mediating role of these molecular traits in the relationship between BMI and endometrial cancer.

40 Methods and Findings: Genetic instruments to proxy 14 molecular risk factors and BMI were

41 constructed by identifying single-nucleotide polymorphisms (SNPs) reliably associated ($P < 5.0 \times 10^{-8}$)

42 with each respective risk factor in previous genome-wide association studies (GWAS). Summary

43 statistics for the association of these SNPs with overall and subtype-specific endometrial cancer risk

44 (12,906 cases and 108,979 controls) were obtained from a GWAS meta-analysis of the Endometrial

45 Cancer Association Consortium (ECAC), Epidemiology of Endometrial Cancer Consortium (E2C2), and UK

46 Biobank. SNPs were combined into multi-allelic models and odds ratios (ORs) and 95% confidence

47 intervals (95% CIs) were generated using inverse-variance weighted random-effects models. The

48 mediating roles of the molecular risk factors in the relationship between BMI and endometrial cancer

49 were then estimated using multivariable MR. In MR analyses, there was strong evidence that BMI (OR

50 per SD increase: 1.88, 95% CI: 1.69 to 2.09, $P = 3.87 \times 10^{-31}$), total testosterone (OR per inverse normal

51 transformed nmol/L increase: 1.64, 95% CI: 1.43 to 1.88, $P = 1.71 \times 10^{-12}$), bioavailable testosterone (OR

52 per inverse normal transformed nmol/L increase: 1.46, 95% CI: 1.29 to 1.65, $P = 3.48 \times 10^{-9}$), fasting

53 insulin (OR per natural log transformed pmol/L increase: 3.93, 95% CI: 2.29 to 6.74, $P = 7.18 \times 10^{-7}$) and

54 sex hormone-binding globulin (SHBG, OR per inverse normal transformed nmol/L increase: 0.71, 95% CI:

55 0.59 to 0.85, $P = 2.07 \times 10^{-4}$) had a causal effect on endometrial cancer risk. Additionally, there was
56 suggestive evidence that total serum cholesterol (OR per mg/dL increase: 0.90, 95% CI: 0.81 to 1.00, $P =$
57 4.01×10^{-2}) had an effect on endometrial cancer risk. In mediation analysis using multivariable MR, we
58 found evidence for a mediating role of fasting insulin (19% total effect mediated, 95% CI: 5 to 34%, $P =$
59 9.17×10^{-3}), bioavailable testosterone (15% mediated, 95% CI: 10 to 20%, $P = 1.43 \times 10^{-8}$), and SHBG (7%
60 mediated, 95% CI: 1 to 12%, $P = 1.81 \times 10^{-2}$) in the relationship between BMI and endometrial cancer
61 risk. The primary limitations of this analysis include the assumption of linear relationships across
62 univariable and multivariable analyses and the restriction of analyses to individuals of European
63 ancestry.

64 Conclusions: Our comprehensive Mendelian randomization analysis provides insight into potential
65 causal mechanisms linking BMI with endometrial cancer risk and suggests pharmacological targeting of
66 insulinemic and hormonal traits as a potential strategy for the prevention of endometrial cancer.

67 Introduction

68 Endometrial cancer is the most common gynaecological cancer in high-income countries and the
69 second most common globally [1, 2]. In 2020, there were 417,367 new cases diagnosed and 97,370
70 endometrial cancer-related deaths worldwide [3]. In contrast to several other cancer types where
71 incidence rates have been declining over the past two decades, the global incidence of endometrial
72 cancer continues to increase [4-8].

73 Elevated body mass index (BMI) is an established risk factor for endometrial cancer and is
74 estimated to confer a larger effect on risk of this malignancy than any other cancer type [9-11]. A recent
75 meta-analysis of 30 prospective studies reported that each 5 kg/m² increase in BMI was associated with
76 a 54% (95% CI: 47 to 61%) higher risk of endometrial cancer [12-14]. It is estimated that excess adiposity
77 accounts for 34% of global endometrial cancer cases, with the increasing incidence of endometrial
78 cancer mirroring rising levels of obesity worldwide [15-17]. Lifestyle and dietary interventions
79 encouraging maintenance of a healthy weight therefore remain cornerstones for the primary prevention
80 of endometrial cancer [9]. Alongside weight management strategies, greater characterisation of the
81 molecular mechanisms underpinning an effect of excess adiposity on endometrial cancer could provide
82 a complementary approach to cancer prevention through the development of pharmacological
83 interventions targeting these traits in high-risk groups.

84 Observational epidemiological studies have reported associations between several hormonal,
85 metabolic, and inflammatory factors linked to obesity and endometrial cancer, including bioavailable
86 testosterone, sex hormone-binding globulin (SHBG), oestradiol and fasting insulin [18-22]. However,
87 conventional observational studies are susceptible to residual confounding (due to unmeasured or
88 imprecisely measured confounders), reverse causation, and other forms of bias which undermine robust

89 causal inference. Therefore, the causal nature of these risk factors, and thus their suitability as effective
90 intervention targets for endometrial cancer prevention, remains unclear.

91 Mendelian randomization (MR) is an analytical approach that uses germline genetic variants as
92 instruments (“proxies”) for risk factors to evaluate the causal effects of these factors on disease
93 outcomes in observational settings [23, 24]. Since germline genetic variants are randomly assorted at
94 meiosis, MR analyses should be less prone to confounding by lifestyle and environmental factors than
95 conventional observational studies. Furthermore, since germline genetic variants are fixed at
96 conception, MR analyses are not subject to reverse causation bias. The statistical power and precision of
97 MR analysis can be increased by employing a “two-sample MR” framework in which summary genetic
98 association data from two independent samples – one representing genetic variant-exposure
99 associations and one representing genetic variant-outcome associations – are synthesised to estimate
100 causal effects [25].

101 Recent MR studies have suggested potential causal relationships between circulating levels of
102 several molecular traits, including low-density lipoprotein (LDL) cholesterol, insulin, total and
103 bioavailable testosterone, and sex hormone-binding globulin (SHBG) and endometrial cancer risk, and
104 have confirmed a causal role of BMI in endometrial cancer risk [17, 26-32]. However, many previously
105 reported molecular risk factors for endometrial cancer from conventional observational studies remain
106 untested in an MR framework, meaning the causal relevance of these factors in disease onset is unclear.
107 Additionally, no MR studies to date have attempted to quantify the potential mediating role of these
108 factors in the relationship between BMI and endometrial cancer risk.

109 Given the unclear causal relevance of previously reported molecular traits in endometrial cancer
110 aetiology, we used a two-sample MR approach to evaluate the causal role of 14 endogenous sex
111 hormones, metabolic traits, and inflammatory markers in endometrial cancer risk (overall and in

112

113 endometrioid and non-endometrioid subtypes). We then used multivariable MR to evaluate and

114 quantify the mediating role of these molecular traits in the relationship between BMI and endometrial

115 cancer risk.

116 **Methods**

117 Our analytical strategy was as follows: first, we attempted to corroborate previous MR findings
118 that there was evidence of a causal relationship between BMI and endometrial cancer risk (overall and
119 by histological subtype); second, we examined evidence for a causal relationship between previously
120 reported molecular factors and endometrial cancer risk (overall and by histological subtype); third, we
121 evaluated the causal relationship between BMI and those molecular risk factors that were confirmed to
122 influence endometrial cancer risk (overall and by histological subtype); finally, we performed a
123 mediation analysis to quantify the proportion of the total effect of BMI on endometrial cancer risk that
124 was mediated by each identified trait.

125

126 *Endometrial cancer study population*

127 Summary genetic association data on overall and subtype-specific endometrial cancer risk were
128 obtained from a genome-wide association study (GWAS) of 12,906 cases (including 8,758 endometrioid
129 and 1,230 non-endometrioid endometrial cancer cases) and up to 108,979 controls of European
130 ancestry [31]. This meta-GWAS combined 17 previously reported studies from the Endometrial Cancer
131 Association Consortium (ECAC), the Epidemiology of Endometrial Cancer Consortium (E2C2), and UK
132 Biobank, with four studies contributing samples to more than one genotyping project. Participants were
133 recruited from Australia, Belgium, Germany, Poland, Sweden, the UK, and the USA and associations
134 were adjusted for principal components of ancestry. Genotyping was performed using one of several
135 Illumina arrays and imputation was performed using the 1000 Genomes Phase 3 reference panel [33].
136 Further information on this meta-GWAS including study-specific genotyping, imputation, and quality
137 control procedures is provided in **S2 Appendix**.

138

139 *Identification of previously reported molecular risk factors for endometrial cancer*

140 We performed two pragmatic searches of the literature using PubMed. The first search
141 identified previously published MR analyses of molecular risk factors for endometrial cancer. The second
142 search identified narrative or systematic reviews of potential molecular mechanisms underpinning the
143 relationship between obesity and endometrial cancer (additional information on search strategies used
144 in literature reviews is presented in **S3 Appendix**). Combined, these literature reviews identified 20
145 unique molecular traits which could mediate the effect of BMI on endometrial cancer risk, of which 14
146 had suitable genetic instruments available. These traits include nine metabolic factors (low-density
147 lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, total serum cholesterol,
148 triglycerides, blood glucose, fasting insulin, insulin-like growth factor 1 (IGF-1), adiponectin, and leptin);
149 three endogenous sex hormones or traits that regulate their bioactivity (total and bioavailable
150 testosterone, and SHBG); and two inflammatory markers (interleukin-6 (IL-6) and C-reactive protein
151 (CRP), measured as high-sensitivity CRP) (**Fig 1**) [29, 34-41]. Summary genetic association data on BMI
152 were obtained from a GWAS of 681,275 individuals of European ancestry [42]. Additional information on
153 participant demographics and covariates included in adjustment strategies across each GWAS are
154 presented in **S4 Table**. All studies contributing data to these analyses had the relevant institutional
155 review board approval from each country, in accordance with the Declaration of Helsinki, and all
156 participants provided informed consent.

157

158 *Statistical analyses*

159 MR analysis can generate unbiased estimates of causal effects of risk factors on disease
160 outcomes if the following assumptions are met: (i) the instrument strongly associates with the exposure
161 (“relevance”), (ii) there is no confounding of the instrument-outcome relationship (“exchangeability”),
162 and (iii) the instrument only affects the outcome through the exposure (“exclusion restriction”) (**Fig. 2**)
163 [43].

164 To construct genetic instruments for BMI and previously reported molecular risk factors, we
165 obtained single-nucleotide polymorphisms (SNPs) reliably ($P < 5 \times 10^{-8}$) and independently ($r^2 < 0.001$)
166 associated with each trait. To construct a genetic instrument for leptin, we restricted genetic variants to
167 *cis*-acting SNPs (i.e. in or within ± 100 kb from the gene encoding the protein). For leptin, IL-6 and CRP
168 analyses, SNPs were permitted to be in weak linkage disequilibrium (LD) ($r^2 < 0.10$) to maximise
169 instrument strength. For all traits where instruments consisted of SNPs in weak LD (i.e. leptin, IL-6 and
170 CRP), standard errors for causal estimates were inflated to account for correlation between SNPs with
171 reference to the 1000 Genomes Phase 3 reference panel [33, 44].

172 For traits instrumented by a single SNP, the Wald ratio was used to generate effect estimates
173 and the delta method was used to approximate standard errors [45]. For traits instrumented by two or
174 more SNPs, inverse-variance weighted (IVW) random-effects models were used to estimate causal
175 effects [45]. A Bonferroni correction was applied as a heuristic to account for multiple testing in MR
176 analyses for the 15 risk factors (14 molecular traits and BMI) investigated. Results below this threshold
177 were classified as “strong evidence” ($P < 3.33 \times 10^{-3}$ (0.05/15 traits)), whereas results between this
178 threshold and $P < 0.05$ were classified as “suggestive evidence”.

179 When using genetic instruments, there is potential for horizontal pleiotropy - when a genetic
180 variant influences an outcome through a biological pathway independent to the exposure, a violation of
181 the “exclusion restriction” criterion [46]. We evaluated the presence of horizontal pleiotropy by

182 performing various sensitivity analyses. First, for instruments consisting of ≥ 10 SNPs, we re-calculated
183 causal estimates obtained from IVW models using MR-Egger regression, weighted median estimation,
184 and weighted mode estimation (additional information on these sensitivity analyses is provided in **S2**
185 **Appendix**) [46-48]. Each of these models makes different assumptions regarding the nature of
186 horizontal pleiotropy in the genetic instrument and therefore performing all three can provide
187 complementary support to IVW models in evaluating the presence of horizontal pleiotropy. These
188 models were not employed when instruments consisted of < 10 SNPs because of their reduced statistical
189 power to detect horizontal pleiotropy in these settings (additional information on these sensitivity
190 analyses is provided in **S2 Appendix**). Second, we performed “leave-one-out” analyses for all findings
191 showing strong or suggestive evidence of effects in IVW models ($P < 0.05$) for traits where instruments
192 consisted of ≥ 10 SNPs and findings were consistent across MR-Egger, weighted median, and weighted
193 mode sensitivity analyses or where instruments consisted of < 10 SNPs. This approach sequentially
194 removes each SNP from an instrument and then re-calculates the overall effect estimate to examine
195 robustness of findings to individual influential SNPs in IVW models.

196 Instruments were derived from sex-combined GWAS for all traits other than those related to
197 endogenous sex hormones to maximise statistical power where there was limited evidence of sex-
198 specificity of SNP associations. As a sensitivity analysis we also re-performed MR analyses using sex-
199 specific instruments where possible. For BMI, all analyses with strong or suggestive evidence for an
200 effect ($P < 0.05$) were repeated using genome-wide significant ($P < 5.0 \times 10^{-8}$) variants identified in
201 female-specific analyses. Likewise, for fasting insulin and CRP analyses, the effect estimates and
202 standard errors of SNPs used to instrument these traits were replaced with female-specific values where
203 there was previous evidence of sex-specificity of associations (trait-specific criteria for identifying sex-
204 specific effects are presented in **S2 Appendix**). Findings from sex-specific sensitivity analyses are
205 presented in **Tables S8, S17, S28-29**. Finally, Steiger filtering was performed across all analyses to

206 identify and subsequently remove any SNPs which explained more variance in the outcome than the
207 exposure (i.e. suggesting misspecification of the causal direction between traits) [49].

208

209 *Mediation analysis*

210 For all molecular traits that were identified as being on the causal pathway between BMI and
211 endometrial cancer risk, we used multivariable MR to generate estimates of the direct effect (i.e. the
212 remaining effect of the exposure on the outcome when the effect of the candidate mediator on the
213 outcome has been adjusted for) and indirect effect (i.e. the effect of the exposure on the outcome
214 through the candidate mediator) using the product of coefficients method [50]. The proportion of the
215 total effect of BMI on endometrial cancer risk (“proportion mediated”) that was mediated by each
216 molecular trait was calculated using these estimates. In the case of fasting insulin, due to weak
217 instrument bias, several different approaches were employed to attempt to maximise conditional
218 instrument strength (for further information on these analyses see **S2 Appendix**). Standard errors for
219 the proportion mediated were calculated using the delta method [51]. In addition, we aimed to perform
220 additional mediation analyses combining all mediators into a single model to examine the extent to
221 which these mediators influenced endometrial cancer independently or via shared biological pathways
222 (presumed relationships between BMI, fasting insulin, SHBG, bioavailable testosterone, and endometrial
223 cancer risk are presented in **Fig 3**). When all putative mediators were combined into a single model with
224 BMI, however, there was persistent weak instrument bias. Of various alternate approaches examined to
225 minimise this bias, the restriction of models to pairs of mediators (without inclusion of BMI) was found
226 to generate the largest conditional F-statistics for each mediator included in the model (for further
227 information on these analyses see **S2 Appendix**).

228

229 *Sample overlap sensitivity analyses*

230 There was moderate sample overlap (52.2-62.4%) across some analyses which can bias MR
231 estimates toward the confounded observational estimate in the presence of weak instrument bias [52]
232 (**S5 Table**). This bias can be inflated by “Winner’s curse”, in which weights for genetic instruments are
233 derived from discovery samples that overlap with outcome samples. Though instruments in this analysis
234 were constructed from genome-wide significant variants ($P < 5.0 \times 10^{-8}$) which should minimise the
235 possibility of weak instrument bias, we performed the following sensitivity analyses to evaluate whether
236 our findings could be influenced by sample overlap: i) for analyses examining the effect of blood glucose
237 on endometrial cancer risk, we re-performed MR analyses using alternate GWAS data for this trait
238 where there was no sample overlap [53, 54]; ii) for analyses examining the effect of BMI on total
239 testosterone, bioavailable testosterone, SHBG and endometrial cancer, we re-performed MR analyses
240 using alternate GWAS data for BMI where there was no sample overlap [55]; and iii) for analyses
241 examining the effect of total testosterone, bioavailable testosterone, SHBG and IGF-1 on endometrial
242 cancer (where suitable alternate GWAS data were not available), we re-constructed instruments for sex
243 hormones using more conservative P -value thresholds ($P < 5.0 \times 10^{-9}$, $P < 5.0 \times 10^{-10}$) to minimise the
244 potential for inclusion of weak instruments into analyses and then re-performed MR analyses. Similarly,
245 in mediation analysis, due to the presence of sample overlap and possible influence of Winner’s curse,
246 for any trait with sample overlap in the same multivariable MR model the analysis was repeated with a
247 more stringent P value ($P < 5.0 \times 10^{-9}$) used for instrument construction.

248 All statistical analyses were performed using R (Vienna, Austria) version 4.0.2. Additional
249 information on statistical packages used across various analyses is presented in **S2 Appendix**.

250 **Results**

251 *Evaluating the effect of BMI on endometrial cancer risk*

252 In MR analyses, there was strong evidence for an effect of BMI on risk of overall endometrial
253 cancer (odds ratio (OR) per SD (4.7 kg/m²) increase in BMI: 1.88, 95% confidence interval (CI): 1.69 to
254 2.09, $P = 3.87 \times 10^{-31}$) (**Fig 4, Table 2**). This finding was consistent across sensitivity analyses examining
255 evidence of horizontal pleiotropy, including MR-Egger, weighted median, and weighted mode models, in
256 analyses using a female-specific BMI instrument, in analyses exploring potential Winner's curse bias in
257 instrument construction, and in the leave-one-out analysis (**S7 Figure, S8 Table, S9 Table**).

258 In subtype-stratified analyses, there was evidence to support an effect of BMI on risk of both
259 endometrioid (OR per SD (4.7 kg/m²) increase in BMI: 1.89, 95% CI: 1.65 to 2.16, $P = 1.67 \times 10^{-20}$) and
260 non-endometrioid endometrial cancer (OR per SD (4.7 kg/m²) increase in BMI: 1.67, 95% CI: 1.19 to 2.35,
261 $P = 3.03 \times 10^{-3}$) (**Fig 4, Table 2**). These findings were robust to sensitivity analyses for endometrioid
262 endometrial cancer; however, findings were less consistent for non-endometrioid endometrial cancer in
263 sensitivity analyses using female-specific BMI instruments (**S10-11 Figure, S8-9 Table**). Therefore, only
264 overall and endometrioid endometrial cancer were included in follow-up analyses.

265

266 *Evaluating the effect of previously reported molecular risk factors on endometrial cancer risk*

267 When examining the effect of previously reported molecular risk factors on overall endometrial
268 cancer risk, there was strong evidence for an effect of total testosterone (OR per increase in inverse-
269 normal transformed (INT) nmol/L total testosterone: 1.64, 95% CI: 1.43 to 1.88, $P = 1.71 \times 10^{-12}$),
270 bioavailable testosterone (OR per increase in INT nmol/L bioavailable testosterone: 1.46, 95% CI: 1.29 to
271 1.65, $P = 3.48 \times 10^{-9}$), fasting insulin (OR per increase in natural log transformed pmol/L fasting insulin

272 3.93, 95% CI: 2.29 to 6.74, $P = 7.18 \times 10^{-7}$), and SHBG (OR per increase in INT nmol/L SHBG 0.71, 95% CI:
273 0.59 to 0.85, $P = 2.07 \times 10^{-4}$) on endometrial cancer risk (**Fig 5; Table 3**). In addition, there was suggestive
274 evidence for an effect of total serum cholesterol (OR per increase in SD (41.7 mg/dL) total serum
275 cholesterol 0.90, 95% CI: 0.81 to 1.00, $P = 4.01 \times 10^{-2}$) on overall endometrial cancer risk. These findings
276 were consistent across sensitivity analyses (**S12-S16 Figure, S17 Table, S8-S9 Table**).

277 In subtype-stratified analyses, there was strong evidence to support an effect of total
278 testosterone (OR per increase in INT nmol/L total testosterone: 1.60, 95% CI: 1.36 to 1.87, $P = 8.70 \times 10^{-9}$),
279 bioavailable testosterone (OR per increase in INT nmol/L bioavailable testosterone: 1.46, 95% CI: 1.29
280 to 1.65, $P = 3.48 \times 10^{-9}$), fasting insulin (OR per increase in natural log transformed pmol/L fasting insulin:
281 4.64, 95% CI: 2.30 to 9.36, $P = 1.84 \times 10^{-5}$), and SHBG (OR per increase in INT nmol/L SHBG: 0.65, 95% CI:
282 0.54 to 0.80, $P = 3.31 \times 10^{-5}$) on endometrioid endometrial cancer risk (**Fig 5; Table 3**). Findings were
283 consistent across all sensitivity analyses (**S19-S22 Figure, S9 Table, S17 Table**).

284

285 *Evaluating the effect of BMI on previously reported molecular risk factors*

286 When examining the effect of BMI on molecular traits confirmed to have a causal effect on
287 endometrial cancer (either overall or endometrioid subtype), there was evidence for an effect of BMI on
288 fasting insulin (change in natural log transformed fasting insulin: 0.17, 95% CI: 0.15 to 0.19, $P = 1.51 \times 10^{-74}$),
289 SHBG (change in INT SHBG: -0.17, 95% CI: -0.19 to -0.16, $P = 4.86 \times 10^{-125}$), bioavailable testosterone
290 (change in INT bioavailable testosterone: 0.26, 95% CI: 0.23 to 0.29, $P = 9.97 \times 10^{-68}$), total testosterone
291 (change in INT total testosterone: 0.08, 95% CI: 0.05 to 0.11, $P = 9.04 \times 10^{-10}$), and CRP (change in ln-
292 transformed CRP: 0.35, 95% CI: 0.32 to 0.38, $P = 2.67 \times 10^{-127}$) (**Fig 6; Table 4**). The direction of effect in
293 MR analyses examining the effect of BMI on total testosterone was inconsistent when employing a
294 weighted mode model, suggesting the potential presence of horizontal pleiotropy. Although there was

295 little evidence for a causal effect of BMI on total serum cholesterol in the IVW model, there was some
296 evidence for an effect across all three MR sensitivity analysis models, suggesting that horizontal
297 pleiotropy may be biasing the IVW estimate towards the null. All other findings were consistent across
298 the various sensitivity analyses (**S23-S27 Figure, S8 Table, S17-S18 Table**).

299

300 *Mendelian randomization mediation analysis*

301 In mediation analyses evaluating the potential mediating role of molecular traits previously
302 shown to be on the causal pathway between BMI and endometrial cancer, there was evidence for a
303 mediating role of bioavailable testosterone (15% mediated, 95% CI: 10 to 20%, $P = 1.43 \times 10^{-8}$), fasting
304 insulin (11% of total effect mediated, 95% CI: 1 to 21%, $P = 2.89 \times 10^{-2}$), and SHBG (7% mediated, 95% CI:
305 1 to 12%, $P = 1.81 \times 10^{-2}$) in the relationship between BMI and overall endometrial cancer risk (**Table 5**).
306 There was also evidence for a mediating role of bioavailable testosterone (15% mediated, 95% CI: 9 to
307 22%, $P = 2.15 \times 10^{-6}$) and fasting insulin (16% mediated, 95% CI: 1 to 21%, $P = 2.89 \times 10^{-2}$) in the
308 relationship between BMI and endometrioid endometrial cancer risk (**Table 5**). Although there was little
309 evidence for a mediating role of SHBG in the relationship between sex-combined BMI and endometrioid
310 endometrial cancer (2% mediated, 95% CI: -9 to 14%, $P = 6.87 \times 10^{-1}$), in the female-specific BMI
311 sensitivity analysis there was strong evidence for a mediating role of female-specific SHBG in the
312 relationship between BMI and endometrioid endometrial cancer (8% mediated, 95% CI: 3 to 13%, $P =$
313 3.38×10^{-3}). Other than this, findings were consistent across sex-specific BMI, fasting insulin and CRP
314 sensitivity analyses (**S28-S29 Table**).

315 The conditional F-statistic for both fasting insulin ($F=2$) and BMI ($F=6$) in the multivariable MR
316 performed to evaluate the “proportion mediated” by fasting insulin was < 10 , indicating that there may

317 be weak instrument bias in these analyses (i.e. over- or underestimation of the “proportion mediated”
318 by fasting insulin) [56]. When re-performing the “proportion mediated” analysis for fasting insulin using
319 an alternative approach (i.e. using an alternative fasting insulin instrument with a larger sample size and
320 limiting the number of SNPs included in the BMI instrument to the 100 with the strongest evidence of
321 association using an LD threshold $r^2 < 0.001$), we found that fasting insulin mediated 19% (95% CI: 5 to
322 34%, $P = 9.17 \times 10^{-3}$) of the relationship between BMI and overall endometrial cancer risk and 21% (95%
323 CI: 5 to 38%, $P = 1.17 \times 10^{-2}$) of the relationship between BMI and endometrioid endometrial cancer risk
324 (**S30 Table**).

325 In mediation analyses combining pairs of mediators into a single model, the effect of fasting
326 insulin on overall endometrial cancer risk attenuated (~40% log OR reduction) when SHBG (a presumed
327 downstream mediator of fasting insulin) was included in the model (OR per increase in natural log
328 transformed pmol/L fasting insulin: 2.28, 95% CI: 1.34 to 3.86, $P = 2.85 \times 10^{-3}$). The effect of SHBG on
329 overall endometrial cancer attenuated fully when bioavailable testosterone (a presumed downstream
330 mediator of SHBG) was included in the model (OR per increase in INT nmol/L SHBG: 1.08, 95% CI: 0.86 to
331 1.36, $P = 5.00 \times 10^{-1}$) (**S34 Table**). The effect of fasting insulin on overall endometrial cancer was strongly
332 attenuated when bioavailable testosterone was included in the model (OR per increase in natural log
333 transformed pmol/L fasting insulin: 1.22, 95% CI: 0.48 to 3.11, $P = 6.78 \times 10^{-1}$), which could reflect
334 mediation of the effect of fasting insulin on endometrial cancer via bioavailable testosterone or the
335 presence of conditionally weak instruments in this model. This could result in over- or underestimation
336 of the proportion of the effect of fasting insulin mediated by bioavailable testosterone.

337 For the endometrioid histological subtype, using the same approach, the effect of fasting insulin
338 on endometrioid endometrial cancer did not markedly change (~14% logOR reduction) when SHBG was
339 included in the model (OR per increase in natural log transformed pmol/L fasting insulin: 3.74, 95% CI:

340 0.74 to 19.01, $P = 1.56 \times 10^{-1}$). However, the effect of SHBG on endometrioid endometrial cancer
341 attenuated fully when bioavailable testosterone was included in the model (OR per increase in INT
342 nmol/L SHBG: 1.16, 95% CI: 0.81 to 1.65, $P = 4.12 \times 10^{-1}$). As with analyses of overall endometrial cancer,
343 when fasting insulin and bioavailable testosterone were combined into a single model, the effect of
344 fasting insulin on endometrioid endometrial cancer attenuated toward the null (OR per increase in
345 natural log transformed pmol/L fasting insulin: 1.05, 95% CI: 0.36 to 3.03, $P = 9.33 \times 10^{-1}$), potentially
346 reflecting mediation via bioavailable testosterone or persistent weak instrument bias in this model.

347 **Discussion**

348 Our systematic Mendelian randomization (MR) analysis of 14 previously reported molecular risk
349 factors and body mass index (BMI) in 12,906 endometrial cancer cases and 108,979 controls provided
350 evidence for roles of elevated BMI, fasting insulin, total and bioavailable testosterone, and sex
351 hormone-binding globulin (SHBG) in risk of overall and endometrioid endometrial cancer. In mediation
352 analyses, we found evidence that fasting insulin, bioavailable testosterone concentrations, and SHBG
353 partially mediated the effect of BMI on overall endometrial cancer risk. When combining pairs of
354 mediators together into a single model, we found evidence that an effect of fasting insulin on
355 endometrial cancer was partially mediated by SHBG levels and that an effect of SHBG on endometrial
356 cancer was largely mediated by bioavailable testosterone levels. An effect of fasting insulin on
357 endometrial cancer risk was also strongly attenuated upon adjustment for bioavailable testosterone
358 levels which could reflect mediation of this effect by bioavailable testosterone or conditionally weak
359 instrument bias for fasting insulin concentrations in this analysis. Our analyses found little evidence that
360 several previously reported molecular risk factors, including several metabolic factors (e.g. LDL-C, HDL-C,
361 IGF-1, adiponectin, leptin) and inflammatory markers (CRP, IL-6), were causally implicated in overall or
362 endometrioid endometrial cancer risk.

363 Several of the findings in this analysis are consistent with evidence from prior conventional
364 observational and MR analyses. For example, the effect of BMI on endometrial cancer risk and the
365 stronger evidence of an effect on endometrioid, as compared to non-endometrioid, endometrial cancer
366 is well-established in the literature and has been shown previously in an MR analysis that used an
367 alternative strategy for instrument construction. Our findings supporting a causal effect of BMI on
368 endometrial cancer risk (OR 1.88, 95% CI: 1.69 to 2.09 per SD (4.7 kg/m²) increase) are larger in
369 magnitude than those from pooled analyses of conventional observational analyses (e.g. the World

370 Cancer Research Fund (WCRF) pooled analysis of 26 prospective studies: RR 1.50, 95% CI 1.42 to 1.59
371 per 5.0 kg/m² increase), consistent with previous comparisons of observational and MR estimates across
372 other cancer sites [57, 58]. Smaller magnitudes of effect in observational analyses may reflect regression
373 dilution bias from single time-point measurements of BMI and/or reverse causation from cancer-
374 induced weight loss, whereas MR estimates reflect accumulated exposure across the life-course and are
375 unlikely to be influenced by reverse causation [59].

376 In agreement with previous MR analyses, our results suggest a causal role of fasting insulin, total
377 and bioavailable testosterone, and SHBG in endometrial cancer risk, although these previous reports
378 either employed smaller sample sizes than this analysis (e.g. fasting insulin analyses were performed in
379 1,287 endometrial cancer cases vs 12,906 cases in our analysis) or used somewhat differing methods to
380 examine instrumental variable assumptions [28-30]. The restriction of an effect of BMI to bioavailable
381 (and not total) testosterone is in agreement with previous observational studies which have suggested
382 that BMI influences testosterone levels through decreased production of SHBG rather than a direct
383 effect on testosterone production [60-64]. Additionally, important mediating roles of fasting insulin,
384 bioavailable testosterone, and SHBG in the relationship between BMI and endometrial cancer are
385 consistent with studies of bariatric surgery which have suggested protective effects of this procedure
386 against endometrial cancer risk, along with reductions in insulin and bioavailable testosterone levels,
387 and increases in SHBG levels [65-73]. Our findings supporting a role of BMI on these traits are also
388 consistent with the important endocrine function of adipose tissue, which is involved in sex steroid
389 metabolism [62, 74-79].

390 Potential aetiological roles of the molecular mediators identified in this analysis are consistent
391 with the “unopposed oestrogen” hypothesis which postulates that endometrial carcinogenesis is driven
392 by excess endogenous or exogenous oestrogen levels that are unopposed by progesterone [80-82]. We

393 were unable to incorporate oestrogen into this analysis as we were unable to identify reliable genetic
394 instruments for this trait. All three of the molecular mediators highlighted in this analysis, however, are
395 known to influence oestrogen: bioavailable testosterone is aromatized to oestradiol; SHBG binds with
396 high-affinity to both oestradiol and bioavailable testosterone [82-87]; and insulin increases androgen
397 and decreases SHBG production [88-91]. We found that an inverse effect of SHBG on endometrial cancer
398 risk was largely attenuated upon adjustment for bioavailable testosterone, suggesting a protective
399 effect of SHBG may be driven via binding of biologically active fractions of circulating testosterone. The
400 attenuation of an effect of fasting insulin on endometrial cancer upon adjustment for bioavailable
401 testosterone could reflect mediation of this effect or the presence of conditionally weak instrument bias
402 in this model. In support of the latter explanation, there is biological evidence that hyperinsulinemia and
403 insulin resistance influence endometrial cancer via oestrogen-independent pathways. For example,
404 insulin has been shown to bind directly to endometrial cells and promote proliferation, and can activate
405 two pathways known to have an important role in carcinogenesis – the phosphatidylinositol-3-kinase-
406 protein kinase B/Akt (PI3K-PKB/Akt) and Ras/Raf/mitogen-activated protein kinase (Ras/Raf/MAPK)
407 pathways [91-96].

408 Some findings from this MR analysis are not in agreement with evidence from previous
409 conventional observational studies. For example, our analyses found little evidence to support causal
410 roles of several metabolic traits (e.g. circulating HDL-cholesterol, triglycerides, adiponectin, leptin) and
411 inflammatory markers (CRP, IL-6) in endometrial cancer risk, despite these traits being linked to
412 endometrial cancer risk in conventional observational analyses [18-22]. Several of these traits (e.g. HDL-
413 cholesterol, LDL-cholesterol, triglycerides) represent highly correlated metabolic perturbations
414 associated with the obese phenotype which may be too clustered to disentangle using conventional
415 multivariable regression methods [97]. Consequently, some of the divergence in findings across previous
416 conventional observational studies and this MR analysis could reflect residual confounding in the

417 former. Another potential explanation for divergence in findings is the susceptibility of conventional
418 observational studies to reverse causation (i.e., latent, undiagnosed endometrial cancer influencing
419 levels of a presumed exposure). For example, a previously reported association of circulating IL-6
420 concentrations with endometrial cancer risk could reflect IL-6 secretion by endometrial cancer-
421 associated fibroblasts rather than a role of IL-6 in endometrial cancer development [98, 99].

422 We were unable to replicate a previously reported MR-based inverse association of LDL
423 cholesterol levels and endometrial cancer risk in the Endometrial Cancer Association Consortium (IVW
424 OR per SD increase in LDL cholesterol: 0.90, 95% CI: 0.85 to 0.95, $P = 8.39 \times 10^{-5}$). In the previous
425 analysis, SNPs were permitted to be in weak linkage disequilibrium (LD) (pairwise correlation $r^2 < 0.05$ vs
426 $r^2 < 0.001$ in our analysis) and a Heterogeneity in Dependent Instruments (HEIDI) test was performed to
427 identify potentially pleiotropic SNPs, resulting in the removal of 6 such SNPs from the 146 SNPs initially
428 used as an instrument. We attempted to replicate these previously reported findings using a more
429 stringent r^2 threshold (i.e. $r^2 < 0.001$) followed by use of the HEIDI test (resulting in the removal of 2
430 potentially pleiotropic SNPs) which resulted in a causal estimate that was closer in magnitude to that
431 previously reported (IVW OR 0.93, 95% CI: 0.86 to 1.00, $P = 4.10 \times 10^{-2}$) (**S45 Table**). However, there was
432 greater imprecision in our estimate compared to this previous analysis which could reflect the more
433 liberal LD threshold employed in this earlier analysis.

434 Our MR analysis provides key insights into potential molecular pathways linking excess adiposity
435 to endometrial cancer risk. This analysis has several strengths including the use of a systematic approach
436 to collate previously reported molecular risk factors for endometrial cancer; the appraisal of their causal
437 relevance in overall and endometrioid endometrial cancer aetiology using an MR framework which
438 should be less prone to conventional issues of confounding and cannot be influenced by reverse
439 causation; the employment of several complementary sensitivity analyses to rigorously assess for

440 violations of MR assumptions; and the use of a summary data-based MR approach which permitted us
441 to leverage large-scale GWAS data from several studies, enhancing statistical power and precision of
442 causal estimates.

443 There are several limitations to our analysis. First, we were unable to evaluate the role of six
444 previously reported molecular risk factors for endometrial cancer due to the absence of reliable genetic
445 instruments for these traits. These six risk factors included oestradiol which is believed to be an
446 important molecular mediator of the effect of BMI on endometrial cancer risk[9]. Second, some of the
447 effect estimates for SNPs included in genetic instruments were obtained from discovery GWAS and have
448 not been replicated in an independent sample which can result in “Winner’s curse” bias. There was
449 sample overlap in this analysis across certain traits; however, the use of conventionally strong ($P < 5.0 \times$
450 10^{-8}) instruments for these traits and the consistency of most findings in sensitivity analyses examining
451 their robustness to potential Winner’s curse bias suggests that this phenomenon was unlikely to
452 markedly influence the results presented in this analysis. Third, although sex-specific sensitivity analyses
453 were performed where data were available, some prior GWAS used in this analysis did not examine for
454 heterogeneity of SNP effects by sex which prevented evaluation of the effect of certain traits on
455 endometrial cancer risk using sex-specific instruments. Fourth, univariable and multivariable MR
456 analyses presented here assume that relationships between exposures and outcomes are linear,
457 although it has been previously suggested that the relationship between BMI and endometrial cancer
458 may best be explained by a non-linear model [12, 100]. Fifth, our analysis was almost exclusively
459 restricted to individuals of European ancestry to minimise bias from population stratification, which may
460 limit the generalisability of our findings to non-European populations. Finally, while various sensitivity
461 analyses were performed to examine violations of exchangeability and exclusion restriction criteria,
462 these assumptions are unverifiable.

463 With the global incidence of overweight and obesity projected to increase and challenges in
464 implementing successful weight loss strategies, pharmacological approaches targeting molecular
465 mediators of the effect of obesity on endometrial cancer development may offer a viable approach for
466 cancer prevention in high-risk groups [101-105]. Metformin, a safe and inexpensive first-line treatment
467 for type 2 diabetes, could serve as a promising chemoprevention agent for endometrial cancer as it
468 increases insulin sensitivity, thus reversing insulin resistance and lowering fasting insulin levels,
469 alongside inhibiting endometrial proliferation [9, 106]. In addition, unlike some other oral
470 hypoglycaemic medications, metformin users show a tendency toward sustained weight loss [107] .
471 Bioavailable testosterone and SHBG also present potential pharmacological targets, though the
472 multifaceted function of these hormones means that targeting these traits may result in adverse effects
473 [108-113]. Phase II clinical trials examining the efficacy of a combination of contraceptive intrauterine
474 devices, metformin, and weight loss interventions as a non-invasive treatment option for individuals
475 with obesity with early-stage endometrial cancer have had encouraging results, and weight loss has
476 been shown to improve oncological outcomes in women with endometrial cancer undergoing progestin
477 treatment [114, 115].

478 Our systematic evaluation of 14 previously reported candidate mediators of the effect of BMI on
479 endometrial cancer risk identifies fasting insulin, bioavailable testosterone, and SHBG as plausible
480 mediators of this relationship. While we were unable to entirely disentangle the independent effects of
481 these three traits, identification of a potential mediating role of these traits (and, in particular, fasting
482 insulin) in endometrial carcinogenesis is nonetheless informative for the development of
483 pharmacological interventions targeting these traits for cancer prevention. In this respect, future
484 assessment of the effect of drugs which target molecular mediators identified in this analysis using a
485 “drug-target Mendelian randomization” approach could inform on the potential efficacy of the
486 repurposing of medications for endometrial cancer prevention.

487 **Conclusion**

488 Our comprehensive Mendelian randomization analysis provides insight into potential causal
489 mechanisms linking excess adiposity to endometrial cancer risk. We show that lifelong cumulative
490 elevated BMI causes a larger increased risk than that reported in previous conventional observational
491 studies. We found strong evidence for a mediating role of fasting insulin, bioavailable testosterone and
492 SHBG in the effect of BMI on endometrial cancer risk. These results suggest pharmacological targeting of
493 insulin-related and hormonal traits as a potential strategy for the prevention of endometrial cancer.

494 **Funding**

495 EH is supported by a Cancer Research UK Population Research Committee Studentship
496 (C18281/A30905). EH, VT, GDS, RMM, KR and JY are supported by Cancer Research UK (C18281/A29019)
497 programme grant (the Integrative Cancer Epidemiology Programme). EH, ES, VT, GDS, RMM, and JY are
498 part of the Medical Research Council Integrative Epidemiology Unit at the University of Bristol which is
499 supported by the Medical Research Council (MC_UU_00011/1, MC_UU_00011/3, MC_UU_00011/6, and
500 MC_UU_00011/4) and the University of Bristol. JY is supported by a Cancer Research UK Population
501 Research Postdoctoral Fellowship (C68933/A28534). RMM is also supported by the NIHR Bristol
502 Biomedical Research Centre which is funded by the NIHR and is a partnership between University
503 Hospitals Bristol and Weston NHS Foundation Trust and the University of Bristol. TMF is funded by the
504 MRC (MR/T002239/1). TAO'M is funded by a National Health and Medical Research Council Investigator
505 Fellowship (APP1173170).

506 Disclaimers: The views expressed are those of the author(s) and not necessarily those of the NHS, the
507 NIHR or the Department of Health and Social Care; where authors are identified as personnel of the
508 International Agency for Research on Cancer/World Health Organization, the authors alone are
509 responsible for the views expressed in this article and they do not necessarily represent the decisions,
510 policy, or views of the International Agency for Research on Cancer/World Health Organization.

511

512 **Acknowledgements**

513 The endometrial cancer genome-wide association analyses were supported by the National Health and
514 Medical Research Council of Australia (APP552402, APP1031333, APP1109286, APP1111246 and
515 APP1061779), the U.S. National Institutes of Health (R01-CA134958), European Research Council (EU
516 FP7 Grant), Wellcome Trust Centre for Human Genetics (090532/Z/09Z) and Cancer Research UK.
517 OncoArray genotyping of ECAC cases was performed with the generous assistance of the Ovarian Cancer

518 Association Consortium (OCAC), which was funded through grants from the U.S. National Institutes of
519 Health (CA1X01HG007491-01 (C.I. Amos), U19-CA148112 (T.A. Sellers), R01-CA149429 (C.M. Phelan) and
520 R01-CA058598 (M.T. Goodman); Canadian Institutes of Health Research (MOP-86727 (L.E. Kelemen))
521 and the Ovarian Cancer Research Fund (A. Berchuck). We particularly thank the efforts of Cathy Phelan.
522 OncoArray genotyping of the BCAC controls was funded by Genome Canada Grant GPH-129344, NIH
523 Grant U19 CA148065, and Cancer UK Grant C1287/A16563. All studies and funders are listed in O'Mara
524 et al (2018). The authors would like to thank the participants of the 1958 British birth cohort (BS58),
525 Academic Medical Centre Amsterdam Premature Atherosclerosis Study (AMC-PAS), Age, Gene/Environment
526 Susceptibility (AGES) study, Anglo-Scandinavian Cardiac Outcome Trial (ASCOT), Aro-Express Biobank
527 Study (AE), Atherosclerosis Risk in Communities (ARIC) study, Atherosclerotic Disease, Vascular Function, and
528 Genetic Epidemiology (ADVANCE) study, Asian Indian Diabetic Heart Study (AIDHS) /Sikh Diabetes Study
529 (SDS), Avon Longitudinal Study of Parents and Children (ALSPAC), Baltimore Longitudinal Study of Aging
530 (BLSA), British Genetics of Hypertension (BRIGHT) Study, Busselton Health Study (BSN), C Reactive
531 Protein Coronary Heart Disease Genetics Collaboration (CCGC), Cancer Prostate in Sweden 1 (CAPS1)
532 study, Cancer Prostate in Sweden 2 (CAPS2) study, CardioGenics study, Cardiovascular Health Study
533 (CHS), Cardiovascular Health Study (CHS), Cardiovascular Risk in Young Finns Study (YFS), Carotid Intima
534 Media Thickness (IMT) and IMT-Progression as Predictors of Vascular Events in a High Risk European
535 Population (IMPROVE) study, Cebu Longitudinal Health and Nutrition Survey (CLHNS), Charles Bronfman
536 Institute for Personalized Medicine (IPM) BioMe Biobank Program, Cohorte Lausannoise (CoLaus) study,
537 Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Inflammation Working Group
538 (CIWG), CROATIA-Vis study, Croatian Study (CROAS), Danish National Birth Cohort (DNBC), Data from an
539 Epidemiological Study on Insulin Resistance syndrome (DESIR), Diabetes Epidemiology: Collaborative
540 analysis of Diagnostic criteria in Europe (DECODE) study, Diabetes Genetics Initiative (DGI), DiaGen
541 consortium, Dose-Responses to Exercise Training (DR's EXTRA) study, Dundee study, Dutch and Belgian

542 Lung Cancer Screening Trial (NELSON), Echinococcus Multilocularis and Internal Diseases in Leutkirch
543 (EMIL) study, Edinburgh Artery Study (EAS), Efficiency and safety of varying frequency of whole blood
544 donation (INTERVAL) study, Ely Study, Endometrial Cancer Association Consortium (ECAC), Epidemiology
545 of Endometrial Cancer Consortium (E2C2), EpiHealth cohort, Erasmus Rucphen Family (ERF) study,
546 Estonian Biobank, Estonian Genome Center of University of Tartu (EGCUT) study, European Prospective
547 Investigation into Cancer and Nutrition (EPIC) study, Family Blood Pressure Program (FBPP), Family
548 Blood Pressure Program (FBPP), Family Heart Study (FamHS), Fast Revascularisation during Instability in
549 Coronary artery disease (FRISCII) study, Fendland study, Finland-United States Investigation of NIDDM
550 Genetics (FUSION) study, FinMetSeq, Finnish Cardiovascular Study (FINCAVAS), Finnish Diabetes
551 Prevention Study (DPS), Finnish Genetic Study of Arrhythmic Events (FinGesture), Finnish National
552 Diabetes Prevention Program (FIN-D2D), Finnish Twin Cohort (FTC), Finrisk study, Framingham Heart
553 Study (FRAM), Genetic Investigation of ANthropometric Traits (GIANT), Gene-Lifestyle interactions And
554 Complex traits Involved in Elevated disease Risk Study (GLACIER), Genetic determinants of Obesity and
555 Metabolic syndrome (DILGOM) study, Genetic Epidemiology Network of Arteriopathy (GENOA) study,
556 Genetic Predisposition of Coronary Heart Disease in Patients Verified with Coronary Angiogram
557 (COROGENE), Genetics of Diabetes Audit and Research Study (GoDartS), GenomEUtwin, German
558 Myocard Infarct Family Study I (GerMiFSI), German Myocard Infarct Family Study II (GerMiFSII), Global
559 Lipids Consortium (GLGC), Gonburg Osteoporosis and Obesity Determinants Study (GOOD), Health 2000
560 study, Health and Retirement Study (HRS), Health, Aging, and Body Composition Study (Health ABC),
561 Health, Risk Factors, Training and Genetics (HERITAGE) Family Study, Heinz Nixdorf Recall (HNR),
562 Hellenic study of Interactions between Single nucleotide polymorphisms and Eating in Atherosclerosis
563 Susceptibility (THISEAS), Helsinki Birth Cohort Study (HBCS), Heredity and Phenotype Intervention (HAPI)
564 Heart Study, Invecchiare in Chianti (InCHIANTI) study, Kingston Gene-by-environment; subset of
565 International Collaborative Study of Hypertension in Blacks (GXE), Kooperative Gesundheitsforschung in

566 der Region Augsburg (KORA) study, Korcula study, Leiden Longevity Study (LLS), Leipzig adults study,
567 Leipzig kids study, Lifelines cohort, London Life Sciences Prospective Population Study (LOLIPOP),
568 LUdwigshafen Risk and Cardiovascular Health (LURIC) study, MAGIC (the Meta-Analyses of Glucose and
569 Insulin-related traits Consortium), Malmo Preventive Project-Re-examination (MPP-RES) study, Malmo
570 Diet and Cancer Study (MDC), Medical research Council (MRC) National Survey of Health & Development
571 (MRC NSHD), Medical Research Council (MRC) National Survey of Health and Development (NSHD),
572 Medical Research Council/Uganda Virus Research Institute General Population Cohort (MRC/UVRIGPC),
573 Metabolic Syndrome in Men (METSIM) study, Microisolates in South Tyrol Study (MICROS), Molecular
574 Genetics of Schizophrenia (MGS), MONica Risk, Genetics, Archiving and Monograph (MORGAM),
575 Multiethnic Cohort Study (MEC), Myocardial Infarction Genetics Consortium (Migen), Nerlands Study of
576 Depression and Anxiety (NESDA), Nerlands Twin Register (NTR), Nijmegen Bladder Cancer Study and
577 Nijmegen Biomedical Study (RUNMC), Nord- Trøndelag Health Study (HUNT), Northern Finland Birth
578 Cohort 1966 (NFBC66), Northern Finland Birth Cohort 1986 (NFBC86), Northern Sweden Population
579 Health Study (NSPHS), Nurse's Health Study (NHS), Orkney Complex Disease Study (ORCADES), Pakistan
580 Risk of Myocardial Infarction Study (PROMIS), Precocious Coronary Artery Disease (PROCARDIS) study,
581 Prevention of RENal and Vascular ENd-stage Disease (PREVEND) study, Prospective Investigation of
582 Vasculature in Uppsala Seniors (PIVUS) study, PROspective study of Pravastatin in Elderly at Risk for
583 vascular disease (PROSPER/PHASE), Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial
584 (PLCO), Quebec Family Study (QFS), Relationship between Insulin Sensitivity and Cardiovascular disease
585 Study (RISC), Rotterdam study, SardiNIA Project, Seychelles Family Study (TANDEM), Sorbs study,
586 Spanish Town study (SPT), STabilization of Arosclerotic plaque By Initiation of darapLadlb rapY
587 (STABILITY), Stanley cohort, Stockholm Coronary Arosclerosis Risk Factor (SCARF) study, Stockholm Heart
588 Epidemiology Program (SHEEP), Studies of Epidemiology and Risk factors in Cancer Heredity / UK
589 Ovarian Cancer Population Study (SEARCH/UKOPS), Study of Health in Pomerania (SHIP), Suivi

590 Temporaire Annuel Non Invasif de la Santé des Lorrains Assurés Sociaux (STANISLAS) cohort, Swedish
591 And Singapore Breast Association Consortium (SASBAC), Swedish Twin Registry (STR), Taichi Consortium,
592 Tracking Adolescents' Individual Lives Survey (TRAILS), Tromsø Study, Twin study at Queensland Institute
593 of Medical Research (QIMR), Twins UK, UK Biobank, Uppsala Longitudinal Study of Adult Men (ULSAM),
594 Vitamin D and Type 2 Diabetes (D2d) study, Wellcome Trust Case Control Consortium (WTCCC),
595 Whitehall study, Women's Genome Health Study (WGHS), and Women's Health Initiative (WHI) for their
596 participation in these studies along with the principal investigators for generating the data utilised for
597 this analysis and for making these data available in the public domain. Data on glycaemic traits have
598 been contributed by MAGIC investigators and have been downloaded from
599 www.magicinvestigators.org, and data on oestradiol and blood glucose have been contributed by the
600 Neale lab and have been downloaded from www.nealelab.is.

601 **References**

- 602 1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics
603 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185
604 countries. *CA: A Cancer Journal for Clinicians*. 2018;68(6):394-424. doi:
605 <https://doi.org/10.3322/caac.21492>.
- 606 2. Howlander N NA, Krapcho M, Miller D, Bishop K, Kosary CL, Yu M, Ruhl J, Tatalovich Z,
607 Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-
608 2014, National Cancer Institute. Bethesda, MD, https://seercancer.gov/csr/1975_2014/. Based
609 on November 2016 SEER data submission, posted to the SEER web site, April 2017.
- 610 3. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer
611 Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in
612 185 Countries. *CA Cancer J Clin*. 2021;71(3):209-49. Epub 2021/02/05. doi: 10.3322/caac.21660.
613 PubMed PMID: 33538338.
- 614 4. Sheikh MA, Althouse AD, Freese KE, Soisson S, Edwards RP, Welburn S, et al. USA
615 Endometrial Cancer Projections to 2030: should we be concerned? *Future Oncology*.
616 2014;10(16):2561-8. doi: 10.2217/fon.14.192. PubMed PMID: 25531045.
- 617 5. Lortet-Tieulent J, Ferlay J, Bray F, Jemal A. International Patterns and Trends in
618 Endometrial Cancer Incidence, 1978–2013. *JNCI: Journal of the National Cancer Institute*.
619 2017;110(4):354-61. doi: 10.1093/jnci/djx214.
- 620 6. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. *CA: A Cancer Journal for Clinicians*.
621 2016;66(1):7-30. doi: <https://doi.org/10.3322/caac.21332>.

- 622 7. Zhang S, Gong T-T, Liu F-H, Jiang Y-T, Sun H, Ma X-X, et al. Global, Regional, and National
623 Burden of Endometrial Cancer, 1990-2017: Results From the Global Burden of Disease Study,
624 2017. *Front Oncol.* 2019;9:1440-. doi: 10.3389/fonc.2019.01440. PubMed PMID: 31921687.
- 625 8. Mullins MA, Cote ML. Beyond Obesity: The Rising Incidence and Mortality Rates of
626 Uterine Corpus Cancer. *J Clin Oncol.* 2019;37(22):1851-3. Epub 2019/06/20. doi:
627 10.1200/JCO.19.01240. PubMed PMID: 31232669.
- 628 9. Onstad MA, Schmandt RE, Lu KH. Addressing the Role of Obesity in Endometrial Cancer
629 Risk, Prevention, and Treatment. *J Clin Oncol.* 2016;34(35):4225-30. Epub 2016/11/07. doi:
630 10.1200/JCO.2016.69.4638. PubMed PMID: 27903150.
- 631 10. Lega IC, Lipscombe LL. Review: Diabetes, Obesity, and Cancer—Pathophysiology and
632 Clinical Implications. *Endocrine Reviews.* 2019;41(1):33-52. doi: 10.1210/endrev/bnz014.
- 633 11. Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D, et al. Cancer incidence and
634 mortality in relation to body mass index in the Million Women Study: cohort study. *BMJ.*
635 2007;335(7630):1134-. Epub 2007/11/06. doi: 10.1136/bmj.39367.495995.AE. PubMed PMID:
636 17986716.
- 637 12. Aune D, Navarro Rosenblatt DA, Chan DS, Vingeliene S, Abar L, Vieira AR, et al.
638 Anthropometric factors and endometrial cancer risk: a systematic review and dose-response
639 meta-analysis of prospective studies. *Ann Oncol.* 2015;26(8):1635-48. Epub 2015/03/21. doi:
640 10.1093/annonc/mdv142. PubMed PMID: 25791635.
- 641 13. World Cancer Research Fund/American Institute for Cancer Research. Continuous
642 Update Project Expert Report 2018. Diet, nutrition, physical activity and ovarian cancer.
643 Available at dietandcancerreport.org.

- 644 14. World Cancer Research Fund/American Institute for Cancer Research. Continuous
645 Update Project Expert Report 2018. Diet, nutrition, physical activity and oesophageal cancer.
646 Available at dietandcancerreport.org.
- 647 15. Nevadunsky NS, Van Arsdale A, Strickler HD, Moadel A, Kaur G, Levitt J, et al. Obesity
648 and age at diagnosis of endometrial cancer. *Obstet Gynecol.* 2014;124(2 Pt 1):300-6. Epub
649 2014/07/09. doi: 10.1097/aog.0000000000000381. PubMed PMID: 25004350.
- 650 16. McCullough ML, Patel AV, Patel R, Rodriguez C, Feigelson HS, Bandera EV, et al. Body
651 mass and endometrial cancer risk by hormone replacement therapy and cancer subtype.
652 *Cancer Epidemiol Biomarkers Prev.* 2008;17(1):73-9. Epub 2008/01/12. doi: 10.1158/1055-
653 9965.Epi-07-2567. PubMed PMID: 18187388.
- 654 17. Painter JN, O'Mara TA, Marquart L, Webb PM, Attia J, Medland SE, et al. Genetic Risk
655 Score Mendelian Randomization Shows that Obesity Measured as Body Mass Index, but not
656 Waist:Hip Ratio, Is Causal for Endometrial Cancer. *Cancer epidemiology, biomarkers &*
657 *prevention : a publication of the American Association for Cancer Research, cosponsored by the*
658 *American Society of Preventive Oncology.* 2016;25(11):1503-10. Epub 2016/08/22. doi:
659 10.1158/1055-9965.EPI-16-0147. PubMed PMID: 27550749.
- 660 18. Dossus L, Rinaldi S, Becker S, Lukanova A, Tjonneland A, Olsen A, et al. Obesity,
661 inflammatory markers, and endometrial cancer risk: a prospective case-control study.
662 *Endocrine-Related Cancer.* 2010;17(4):1007. doi: 10.1677/erc-10-0053.
- 663 19. Friedenreich CM, Langley AR, Speidel TP, Lau DCW, Courneya KS, Csizmadi I, et al. Case-
664 control study of inflammatory markers and the risk of endometrial cancer. *European Journal of*

665 Cancer Prevention. 2013;22(4):374-9. doi: 10.1097/CEJ.0b013e32835b3813. PubMed PMID:
666 00008469-201307000-00013.

667 20. Wang T, Rohan TE, Gunter MJ, Xue X, Wactawski-Wende J, Rajpathak SN, et al. A
668 Prospective Study of Inflammation Markers and Endometrial Cancer Risk in Postmenopausal
669 Hormone Nonusers. Cancer Epidemiology Biomarkers & Prevention. 2011;20(5):971-7. doi:
670 10.1158/1055-9965.Epi-10-1222.

671 21. Lindemann K, Vatten LJ, Ellstrøm-Eng M, Eskild A. Serum lipids and endometrial cancer
672 risk: Results from the HUNT-II study. International Journal of Cancer. 2009;124(12):2938-41.
673 doi: <https://doi.org/10.1002/ijc.24285>.

674 22. Swanson CA, Potischman N, Barrett RJ, Berman ML, Mortel R, Twiggs LB, et al.
675 Endometrial cancer risk in relation to serum lipids and lipoprotein levels. Cancer Epidemiol
676 Biomarkers Prev. 1994;3(7):575-81. Epub 1994/10/01. PubMed PMID: 7827588.

677 23. Yarmolinsky J, Wade KH, Richmond RC, Langdon RJ, Bull CJ, Tilling KM, et al. Causal
678 Inference in Cancer Epidemiology: What Is the Role of Mendelian Randomization? Cancer
679 Epidemiology Biomarkers & Prevention. 2018;27(9):995-1010. doi: 10.1158/1055-
680 9965.Epi-17-1177.

681 24. Davey Smith G, Ebrahim S. 'Mendelian randomization': can genetic epidemiology
682 contribute to understanding environmental determinants of disease?*. International Journal of
683 Epidemiology. 2003;32(1):1-22. doi: 10.1093/ije/dyg070.

684 25. Pierce BL, Burgess S. Efficient design for Mendelian randomization studies: subsample
685 and 2-sample instrumental variable estimators. Am J Epidemiol. 2013;178(7):1177-84. Epub

- 686 2013/07/19. doi: 10.1093/aje/kwt084. PubMed PMID: 23863760; PubMed Central PMCID:
687 PMCPMC3783091.
- 688 26. Thompson DJ, O'Mara TA, Glubb DM, Painter JN, Cheng T, Folkerd E, et al. CYP19A1 fine-
689 mapping and Mendelian randomization: estradiol is causal for endometrial cancer. *Endocr Relat*
690 *Cancer*. 2016;23(2):77-91. Epub 2015/11/18. doi: 10.1530/erc-15-0386. PubMed PMID:
691 26574572; PubMed Central PMCID: PMCPMC4697192.
- 692 27. Kho P-F, Amant F, Annibali D, Ashton K, Attia J, Auer PL, et al. Mendelian randomization
693 analyses suggest a role for cholesterol in the development of endometrial cancer. *International*
694 *Journal of Cancer*. 2021;148(2):307-19. doi: <https://doi.org/10.1002/ijc.33206>.
- 695 28. Nead KT, Sharp SJ, Thompson DJ, Painter JN, Savage DB, Semple RK, et al. Evidence of a
696 Causal Association Between Insulinemia and Endometrial Cancer: A Mendelian Randomization
697 Analysis. *J Natl Cancer Inst*. 2015;107(9). Epub 2015/07/03. doi: 10.1093/jnci/djv178. PubMed
698 PMID: 26134033; PubMed Central PMCID: PMCPMC4572886.
- 699 29. Ruth KS, Day FR, Tyrrell J, Thompson DJ, Wood AR, Mahajan A, et al. Using human
700 genetics to understand the disease impacts of testosterone in men and women. *Nature*
701 *Medicine*. 2020;26(2):252-+. doi: 10.1038/s41591-020-0751-5. PubMed PMID:
702 WOS:000512529400005.
- 703 30. Mullee A, Dimou N, Allen N, O'Mara T, Gunter MJ, Murphy N. Testosterone, sex
704 hormone-binding globulin, insulin-like growth factor-1 and endometrial cancer risk:
705 observational and Mendelian randomization analyses. *Br J Cancer*. 2021;125(9):1308-17. Epub
706 2021/08/08. doi: 10.1038/s41416-021-01518-3. PubMed PMID: 34363033; PubMed Central
707 PMCID: PMCPMC8548546.

- 708 31. O'Mara TA, Glubb DM, Amant F, Annibali D, Ashton K, Attia J, et al. Identification of nine
709 new susceptibility loci for endometrial cancer. *Nat Commun.* 2018;9(1):3166. Epub 2018/08/11.
710 doi: 10.1038/s41467-018-05427-7. PubMed PMID: 30093612; PubMed Central PMCID:
711 PMCPMC6085317.
- 712 32. Dimou NL, Papadimitriou N, Mariosa D, Johansson M, Brennan P, Peters U, et al.
713 Circulating adipokine concentrations and risk of five obesity-related cancers: A Mendelian
714 randomization study. *Int J Cancer.* 2021;148(7):1625-36. Epub 2020/10/11. doi:
715 10.1002/ijc.33338. PubMed PMID: 33038280; PubMed Central PMCID: PMCPMC7894468.
- 716 33. Auton A, Abecasis GR, Altshuler DM, Durbin RM, Abecasis GR, Bentley DR, et al. A global
717 reference for human genetic variation. *Nature.* 2015;526(7571):68-74. doi:
718 10.1038/nature15393.
- 719 34. Willer CJ, Schmidt EM, Sengupta S, Peloso GM, Gustafsson S, Kanoni S, et al. Discovery
720 and refinement of loci associated with lipid levels. *Nature Genetics.* 2013;45(11):1274-+. doi:
721 10.1038/ng.2797. PubMed PMID: WOS:000326384100007.
- 722 35. Scott RA, Lagou V, Welch RP, Wheeler E, Montasser ME, Luan JA, et al. Large-scale
723 association analyses identify new loci influencing glycemic traits and provide insight into the
724 underlying biological pathways. *Nature Genetics.* 2012;44(9):991-+. doi: 10.1038/ng.2385.
725 PubMed PMID: WOS:000308491200010.
- 726 36. Neale B. GWAS results. UK Biobank website. [updated 1st August 2018; cited 2020
727 9/12/20].

- 728 37. Sinnott-Armstrong N, Tanigawa Y, Amar D, Mars NJ, Aguirre M, Venkataraman GR, et al.
729 Genetics of 38 blood and urine biomarkers in the UK Biobank. *bioRxiv*. 2019:660506. doi:
730 10.1101/660506.
- 731 38. Georgakis MK, Malik R, Gill D, Franceschini N, Sudlow CLM, Dichgans M. Interleukin-6
732 signaling effects on ischemic stroke and other cardiovascular outcomes: a Mendelian
733 Randomization study. *medRxiv*. 2019:19007682. doi: 10.1101/19007682.
- 734 39. Dastani Z, Hivert M-F, Timpson N, Perry JRB, Yuan X, Scott RA, et al. Novel Loci for
735 Adiponectin Levels and Their Influence on Type 2 Diabetes and Metabolic Traits: A Multi-Ethnic
736 Meta-Analysis of 45,891 Individuals. *PLOS Genetics*. 2012;8(3):e1002607. doi:
737 10.1371/journal.pgen.1002607.
- 738 40. Sun BB, Maranville JC, Peters JE, Stacey D, Staley JR, Blackshaw J, et al. Genomic atlas of
739 the human plasma proteome. *Nature*. 2018;558(7708):73-9. doi: 10.1038/s41586-018-0175-2.
- 740 41. Ligthart S, Vaez A, Vösa U, Stathopoulou MG, de Vries PS, Prins BP, et al. Genome
741 Analyses of >200,000 Individuals Identify 58 Loci for Chronic Inflammation and Highlight
742 Pathways that Link Inflammation and Complex Disorders. *Am J Hum Genet*. 2018;103(5):691-
743 706. Epub 2018/11/06. doi: 10.1016/j.ajhg.2018.09.009. PubMed PMID: 30388399; PubMed
744 Central PMCID: PMC6218410.
- 745 42. Yengo L, Sidorenko J, Kemper KE, Zheng Z, Wood AR, Weedon MN, et al. Meta-analysis
746 of genome-wide association studies for height and body mass index in ~700000 individuals of
747 European ancestry. *Hum Mol Genet*. 2018;27(20):3641-9. Epub 2018/08/21. doi:
748 10.1093/hmg/ddy271. PubMed PMID: 30124842; PubMed Central PMCID: PMC6488973.

- 749 43. Davies NM, Holmes MV, Davey Smith G. Reading Mendelian randomisation studies: a
750 guide, glossary, and checklist for clinicians. *BMJ*. 2018;362:k601. Epub 2018/07/14. doi:
751 10.1136/bmj.k601. PubMed PMID: 30002074; PubMed Central PMCID: PMC6041728
752 interests and declare that we have no competing interests.
- 753 44. Burgess S, Zuber V, Valdes-Marquez E, Sun BB, Hopewell JC. Mendelian randomization
754 with fine-mapped genetic data: Choosing from large numbers of correlated instrumental
755 variables. *Genetic Epidemiology*. 2017;41(8):714-25. doi: <https://doi.org/10.1002/gepi.22077>.
- 756 45. Hemani G, Bowden J, Davey Smith G. Evaluating the potential role of pleiotropy in
757 Mendelian randomization studies. *Hum Mol Genet*. 2018;27(R2):R195-r208. Epub 2018/05/18.
758 doi: 10.1093/hmg/ddy163. PubMed PMID: 29771313; PubMed Central PMCID:
759 PMCPMC6061876.
- 760 46. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in Mendelian
761 Randomization with Some Invalid Instruments Using a Weighted Median Estimator. *Genet*
762 *Epidemiol*. 2016;40(4):304-14. Epub 2016/04/12. doi: 10.1002/gepi.21965. PubMed PMID:
763 27061298; PubMed Central PMCID: PMC4849733.
- 764 47. Hartwig FP, Davey Smith G, Bowden J. Robust inference in summary data Mendelian
765 randomization via the zero modal pleiotropy assumption. *International journal of epidemiology*.
766 2017;46(6):1985-98. doi: 10.1093/ije/dyx102. PubMed PMID: 29040600.
- 767 48. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments:
768 effect estimation and bias detection through Egger regression. *Int J Epidemiol*. 2015;44(2):512-
769 25. Epub 2015/06/08. doi: 10.1093/ije/dyv080. PubMed PMID: 26050253; PubMed Central
770 PMCID: PMC4469799.

- 771 49. Hemani G, Tilling K, Davey Smith G. Orienting the causal relationship between
772 imprecisely measured traits using GWAS summary data. *PLoS Genet.* 2017;13(11):e1007081.
773 Epub 2017/11/18. doi: 10.1371/journal.pgen.1007081. PubMed PMID: 29149188; PubMed
774 Central PMCID: PMC5711033.
- 775 50. Burgess S, Thompson SG. Multivariable Mendelian Randomization: The Use of
776 Pleiotropic Genetic Variants to Estimate Causal Effects. *American Journal of Epidemiology.*
777 2015;181(4):251-60. doi: 10.1093/aje/kwu283.
- 778 51. Cheung MWL. Comparison of methods for constructing confidence intervals of
779 standardized indirect effects. *Behavior Research Methods.* 2009;41(2):425-38. doi:
780 10.3758/BRM.41.2.425.
- 781 52. Haycock PC, Burgess S, Wade KH, Bowden J, Relton C, Davey Smith G. Best (but oft-
782 forgotten) practices: the design, analysis, and interpretation of Mendelian randomization
783 studies. *Am J Clin Nutr.* 2016;103(4):965-78. doi: 10.3945/ajcn.115.118216. PubMed PMID:
784 26961927.
- 785 53. Kettunen J, Demirkan A, Würtz P, Draisma HH, Haller T, Rawal R, et al. Genome-wide
786 study for circulating metabolites identifies 62 loci and reveals novel systemic effects of LPA. *Nat*
787 *Commun.* 2016;7:11122. Epub 2016/03/24. doi: 10.1038/ncomms11122. PubMed PMID:
788 27005778.
- 789 54. Prins BP, Kuchenbaecker KB, Bao Y, Smart M, Zabaneh D, Fatemifar G, et al. Genome-
790 wide analysis of health-related biomarkers in the UK Household Longitudinal Study reveals
791 novel associations. *Sci Rep.* 2017;7(1):11008. Epub 2017/09/10. doi: 10.1038/s41598-017-
792 10812-1. PubMed PMID: 28887542; PubMed Central PMCID: PMC5591265.

- 793 55. Locke AE, Kahali B, Berndt SI, Justice AE, Pers TH, Felix R, et al. Genetic studies of body
794 mass index yield new insights for obesity biology. *Nature*. 2015;518(7538):197-U401. doi:
795 10.1038/nature14177. PubMed PMID: WOS:000349190300031.
- 796 56. Sanderson E, Spiller W, Bowden J. Testing and Correcting for Weak and Pleiotropic
797 Instruments in Two-Sample Multivariable Mendelian Randomisation. *bioRxiv*.
798 2020:2020.04.02.021980. doi: 10.1101/2020.04.02.021980.
- 799 57. World Cancer Research Fund/American Institute for Cancer Research. Continuous
800 Update Project Expert Report 2018. Diet, nutrition, physical activity and endometrial cancer.
801 Available at dietandcancerreport.org.
- 802 58. Mariosa D, Carreras-Torres R, Martin RM, Johansson M, Brennan P. Commentary: What
803 can Mendelian randomization tell us about causes of cancer? *International Journal of*
804 *Epidemiology*. 2019;48(3):816-21. doi: 10.1093/ije/dyz151.
- 805 59. Morris TT, Heron J, Sanderson E, Smith GD, Tilling K. Interpretation of mendelian
806 randomization using one measure of an exposure that varies over time. *medRxiv*.
807 2021:2021.11.18.21266515. doi: 10.1101/2021.11.18.21266515.
- 808 60. Poddar M, Chetty Y, Chetty VT. How does obesity affect the endocrine system? A
809 narrative review. *Clinical Obesity*. 2017;7(3):136-44. doi: <https://doi.org/10.1111/cob.12184>.
- 810 61. Danforth KN, Eliassen AH, Tworoger SS, Missmer SA, Barbieri RL, Rosner BA, et al. The
811 association of plasma androgen levels with breast, ovarian and endometrial cancer risk factors
812 among postmenopausal women. *International journal of cancer*. 2010;126(1):199-207. doi:
813 10.1002/ijc.24709. PubMed PMID: 19569181.

- 814 62. Penttilä T-L, Koskinen P, Penttilä T-A, Anttila L, Irjala K. Obesity regulates bioavailable
815 testosterone levels in women with or without polycystic ovary syndrome. *Fertility and Sterility*.
816 1999;71(3):457-61. doi: [https://doi.org/10.1016/S0015-0282\(98\)00473-7](https://doi.org/10.1016/S0015-0282(98)00473-7).
- 817 63. Lim SS, Norman RJ, Davies MJ, Moran LJ. The effect of obesity on polycystic ovary
818 syndrome: a systematic review and meta-analysis. *Obesity Reviews*. 2013;14(2):95-109. doi:
819 <https://doi.org/10.1111/j.1467-789X.2012.01053.x>.
- 820 64. Burger HG, Dudley EC, Cui J, Dennerstein L, Hopper JL. A prospective longitudinal study
821 of serum testosterone, dehydroepiandrosterone sulfate, and sex hormone-binding globulin
822 levels through the menopause transition. *J Clin Endocrinol Metab*. 2000;85(8):2832-8. Epub
823 2000/08/18. doi: 10.1210/jcem.85.8.6740. PubMed PMID: 10946891.
- 824 65. Upala S, Anawin S. Bariatric surgery and risk of postoperative endometrial cancer: a
825 systematic review and meta-analysis. *Surgery for Obesity and Related Diseases*. 2015;11(4):949-
826 55. doi: <https://doi.org/10.1016/j.soard.2014.09.024>.
- 827 66. Sjöström L, Gummesson A, Sjöström CD, Narbro K, Peltonen M, Wedel H, et al. Effects of
828 bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects
829 Study): a prospective, controlled intervention trial. *Lancet Oncol*. 2009;10(7):653-62. Epub
830 2009/06/27. doi: 10.1016/s1470-2045(09)70159-7. PubMed PMID: 19556163.
- 831 67. Anderwald CH, Tura A, Promintzer-Schifferl M, Prager G, Stadler M, Ludvik B, et al.
832 Alterations in gastrointestinal, endocrine, and metabolic processes after bariatric Roux-en-Y
833 gastric bypass surgery. *Diabetes Care*. 2012;35(12):2580-7. Epub 2012/08/28. doi:
834 10.2337/dc12-0197. PubMed PMID: 22923664; PubMed Central PMCID: PMC3507557.

- 835 68. Sdralis E, Argentou M, Mead N, Kehagias I, Alexandridis T, Kalfarentzos F. A Prospective
836 Randomized Study Comparing Patients with Morbid Obesity Submitted to Sleeve Gastrectomy
837 With or Without Omentectomy. *Obesity Surgery*. 2013;23(7):965-71. doi: 10.1007/s11695-013-
838 0925-z.
- 839 69. Beiglböck H, Fellingner P, Ranzenberger-Haider T, Itariu B, Prager G, Kautzky-Willer A, et
840 al. Pre-operative Obesity-Associated Hyperandrogenemia in Women and Hypogonadism in Men
841 Have No Impact on Weight Loss Following Bariatric Surgery. *Obesity Surgery*. 2020;30(10):3947-
842 54. doi: 10.1007/s11695-020-04761-4.
- 843 70. Ernst B, Wilms B, Thurnheer M, Schultes B. Reduced circulating androgen levels after
844 gastric bypass surgery in severely obese women. *Obes Surg*. 2013;23(5):602-7. Epub
845 2012/11/29. doi: 10.1007/s11695-012-0823-9. PubMed PMID: 23188476.
- 846 71. Bastounis EA, Karayiannakis AJ, Syrigos K, Zbar A, Makri GG, Alexiou D. Sex hormone
847 changes in morbidly obese patients after vertical banded gastroplasty. *Eur Surg Res*.
848 1998;30(1):43-7. Epub 1998/03/11. doi: 10.1159/000008556. PubMed PMID: 9493693.
- 849 72. Dashti SG, English DR, Simpson JA, Karahalios A, Moreno-Betancur M, Biessy C, et al.
850 Adiposity and Endometrial Cancer Risk in Postmenopausal Women: A Sequential Causal
851 Mediation Analysis. *Cancer Epidemiol Biomarkers Prev*. 2021;30(1):104-13. Epub 2020/10/04.
852 doi: 10.1158/1055-9965.Epi-20-0965. PubMed PMID: 33008875.
- 853 73. Pournaras DJ, Osborne A, Hawkins SC, Vincent RP, Mahon D, Ewings P, et al. Remission
854 of type 2 diabetes after gastric bypass and banding: mechanisms and 2 year outcomes. *Ann*
855 *Surg*. 2010;252(6):966-71. Epub 2010/11/26. doi: 10.1097/SLA.0b013e3181efc49a. PubMed
856 PMID: 21107106.

- 857 74. ter Horst KW, Gilijamse PW, Koopman KE, de Weijer BA, Brands M, Kootte RS, et al.
858 Insulin resistance in obesity can be reliably identified from fasting plasma insulin. International
859 Journal of Obesity. 2015;39(12):1703-9. doi: 10.1038/ijo.2015.125.
- 860 75. Brochu M, Mathieu M-E, Karelis AD, Doucet É, Lavoie M-E, Garrel D, et al. Contribution
861 of the Lean Body Mass to Insulin Resistance in Postmenopausal Women With Visceral Obesity:
862 A Monet Study. Obesity. 2008;16(5):1085-93. doi: <https://doi.org/10.1038/oby.2008.23>.
- 863 76. Trapp EG, Chisholm DJ, Freund J, Boutcher SH. The effects of high-intensity intermittent
864 exercise training on fat loss and fasting insulin levels of young women. International Journal of
865 Obesity. 2008;32(4):684-91. doi: 10.1038/sj.ijo.0803781.
- 866 77. Ross R, Janssen I, Dawson J, Kungl A-M, Kuk JL, Wong SL, et al. Exercise-Induced
867 Reduction in Obesity and Insulin Resistance in Women: a Randomized Controlled Trial. Obesity
868 Research. 2004;12(5):789-98. doi: <https://doi.org/10.1038/oby.2004.95>.
- 869 78. Wei S, Schmidt MD, Dwyer T, Norman RJ, Venn AJ. Obesity and Menstrual Irregularity:
870 Associations With SHBG, Testosterone, and Insulin. Obesity. 2009;17(5):1070-6. doi:
871 <https://doi.org/10.1038/oby.2008.641>.
- 872 79. Tchernof A, Després J-P. Sex steroid hormones, sex hormone-binding globulin, and
873 obesity in men and women. Hormone and Metabolic Research. 2000;32(11/12):526-36.
- 874 80. Henderson BE, Ross RK, Pike MC, Casagrande JT. Endogenous hormones as a major
875 factor in human cancer. Cancer Res. 1982;42(8):3232-9. Epub 1982/08/01. PubMed PMID:
876 7046921.
- 877 81. Key TJ, Pike MC. The dose-effect relationship between 'unopposed' oestrogens and
878 endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Br

- 879 J Cancer. 1988;57(2):205-12. Epub 1988/02/01. doi: 10.1038/bjc.1988.44. PubMed PMID:
880 3358913; PubMed Central PMCID: PMCPMC2246441.
- 881 82. Kaaks R, Lukanova A, Kurzer MS. Obesity, endogenous hormones, and endometrial
882 cancer risk: a synthetic review. *Cancer Epidemiol Biomarkers Prev.* 2002;11(12):1531-43. Epub
883 2002/12/24. PubMed PMID: 12496040.
- 884 83. Bélanger C, Luu-The V, Dupont P, Tchernof A. Adipose tissue intracrinology: potential
885 importance of local androgen/estrogen metabolism in the regulation of adiposity. *Horm Metab*
886 *Res.* 2002;34(11-12):737-45. Epub 2003/03/28. doi: 10.1055/s-2002-38265. PubMed PMID:
887 12660892.
- 888 84. Somboonporn W, Davis SR. Testosterone Effects on the Breast: Implications for
889 Testosterone Therapy for Women. *Endocrine Reviews.* 2004;25(3):374-88. doi:
890 10.1210/er.2003-0016.
- 891 85. Bulun SE, Lin Z, Imir G, Amin S, Demura M, Yilmaz B, et al. Regulation of Aromatase
892 Expression in Estrogen-Responsive Breast and Uterine Disease: From Bench to Treatment.
893 *Pharmacological Reviews.* 2005;57(3):359-83. doi: 10.1124/pr.57.3.6.
- 894 86. Simó R, Sáez-López C, Barbosa-Desongles A, Hernández C, Selva DM. Novel insights in
895 SHBG regulation and clinical implications. *Trends Endocrinol Metab.* 2015;26(7):376-83. Epub
896 2015/06/06. doi: 10.1016/j.tem.2015.05.001. PubMed PMID: 26044465.
- 897 87. Grasa MDM, Gulfo J, Camps N, Alcalá R, Monserrat L, Moreno-Navarrete JM, et al.
898 Modulation of SHBG binding to testosterone and estradiol by sex and morbid obesity. *Eur J*
899 *Endocrinol.* 2017;176(4):393-404. Epub 2017/01/13. doi: 10.1530/eje-16-0834. PubMed PMID:
900 28077498.

- 901 88. Suba Z. Interplay between insulin resistance and estrogen deficiency as co- activators in
902 carcinogenesis. *Pathol Oncol Res.* 2012;18(2):123-33. Epub 2011/10/11. doi: 10.1007/s12253-
903 011-9466-8. PubMed PMID: 21984197.
- 904 89. Maturana MA, Spritzer PM. Association between hyperinsulinemia and endogenous
905 androgen levels in peri- and postmenopausal women. *Metabolism.* 2002;51(2):238-43. doi:
906 <https://doi.org/10.1053/meta.2002.29997>.
- 907 90. Weinberg ME, Manson JE, Buring JE, Cook NR, Seely EW, Ridker PM, et al. Low sex
908 hormone-binding globulin is associated with the metabolic syndrome in postmenopausal
909 women. *Metabolism.* 2006;55(11):1473-80. doi:
910 <https://doi.org/10.1016/j.metabol.2006.06.017>.
- 911 91. Mu N, Zhu Y, Wang Y, Zhang H, Xue F. Insulin resistance: a significant risk factor of
912 endometrial cancer. *Gynecol Oncol.* 2012;125(3):751-7. Epub 2012/03/28. doi:
913 10.1016/j.ygyno.2012.03.032. PubMed PMID: 22449736.
- 914 92. Haeusler RA, McGraw TE, Accili D. Biochemical and cellular properties of insulin receptor
915 signalling. *Nature Reviews Molecular Cell Biology.* 2018;19(1):31-44. doi: 10.1038/nrm.2017.89.
- 916 93. Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Manson JE, Li J, et al. A prospective
917 evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer.
918 *Cancer epidemiology, biomarkers & prevention : a publication of the American Association for*
919 *Cancer Research, cosponsored by the American Society of Preventive Oncology.*
920 2008;17(4):921-9. doi: 10.1158/1055-9965.EPI-07-2686. PubMed PMID: 18398032.

- 921 94. Ogawa K, Sun C, Horii A. Exploration of genetic alterations in human endometrial cancer
922 and melanoma: distinct tumorigenic pathways that share a frequent abnormal PI3K/AKT
923 cascade. *Oncol Rep.* 2005;14(6):1481-5. Epub 2005/11/08. PubMed PMID: 16273242.
- 924 95. Slomovitz BM, Coleman RL. The PI3K/AKT/mTOR pathway as a therapeutic target in
925 endometrial cancer. *Clin Cancer Res.* 2012;18(21):5856-64. Epub 2012/10/20. doi:
926 10.1158/1078-0432.Ccr-12-0662. PubMed PMID: 23082003.
- 927 96. Weigelt B, Warne PH, Lambros MB, Reis-Filho JS, Downward J. PI3K Pathway
928 Dependencies in Endometrioid Endometrial Cancer Cell Lines. *Clinical Cancer Research.*
929 2013;19(13):3533-44. doi: 10.1158/1078-0432.Ccr-12-3815.
- 930 97. Phillips AN, Smith GD. How independent are “independent” effects? relative risk
931 estimation when correlated exposures are measured imprecisely. *Journal of Clinical*
932 *Epidemiology.* 1991;44(11):1223-31. doi: 10.1016/0895-4356(91)90155-3.
- 933 98. Subramaniam KS, Tham ST, Mohamed Z, Woo YL, Mat Adenan NA, Chung I. Cancer-
934 associated fibroblasts promote proliferation of endometrial cancer cells. *PLoS One.*
935 2013;8(7):e68923. Epub 2013/08/08. doi: 10.1371/journal.pone.0068923. PubMed PMID:
936 23922669; PubMed Central PMCID: PMC3724864.
- 937 99. Subramaniam KS, Omar IS, Kwong SC, Mohamed Z, Woo YL, Mat Adenan NA, et al.
938 Cancer-associated fibroblasts promote endometrial cancer growth via activation of interleukin-
939 6/STAT-3/c-Myc pathway. *Am J Cancer Res.* 2016;6(2):200-13. Epub 2016/05/18. PubMed
940 PMID: 27186396; PubMed Central PMCID: PMC4859653.

- 941 100. Renehan AG, Soerjomataram I, Tyson M, Egger M, Zwahlen M, Coebergh JW, et al.
942 Incident cancer burden attributable to excess body mass index in 30 European countries.
943 International Journal of Cancer. 2010;126(3):692-702. doi: <https://doi.org/10.1002/ijc.24803>.
- 944 101. Ochner CN, Tsai AG, Kushner RF, Wadden TA. Treating obesity seriously: when
945 recommendations for lifestyle change confront biological adaptations. The Lancet Diabetes &
946 Endocrinology. 2015;3(4):232-4. doi: 10.1016/S2213-8587(15)00009-1.
- 947 102. Evert AB, Franz MJ. Why Weight Loss Maintenance Is Difficult. Diabetes Spectrum.
948 2017;30(3):153-6. doi: 10.2337/ds017-0025.
- 949 103. Abarca-Gómez L, Abdeen ZA, Hamid ZA, Abu-Rmeileh NM, Acosta-Cazares B, Acuin C, et
950 al. Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to
951 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million
952 children, adolescents, and adults. The Lancet. 2017;390(10113):2627-42. doi: 10.1016/S0140-
953 6736(17)32129-3.
- 954 104. Wang Y, Beydoun MA, Min J, Xue H, Kaminsky LA, Cheskin LJ. Has the prevalence of
955 overweight, obesity and central obesity levelled off in the United States? Trends, patterns,
956 disparities, and future projections for the obesity epidemic. International Journal of
957 Epidemiology. 2020;49(3):810-23. doi: 10.1093/ije/dyz273.
- 958 105. Pineda E, Sanchez-Romero LM, Brown M, Jaccard A, Jewell J, Galea G, et al. Forecasting
959 Future Trends in Obesity across Europe: The Value of Improving Surveillance. Obesity Facts.
960 2018;11(5):360-71. doi: 10.1159/000492115.
- 961 106. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, et al. Role of AMP-activated
962 protein kinase in mechanism of metformin action. J Clin Invest. 2001;108(8):1167-74. Epub

- 963 2001/10/17. doi: 10.1172/jci13505. PubMed PMID: 11602624; PubMed Central PMCID:
964 PMCPMC209533.
- 965 107. Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, Brenneman AT, et al.
966 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program
967 Outcomes Study. *Lancet*. 2009;374(9702):1677-86. Epub 2009/11/03. doi: 10.1016/s0140-
968 6736(09)61457-4. PubMed PMID: 19878986; PubMed Central PMCID: PMCPMC3135022.
- 969 108. Boccardo F, Guarneri D, Rubagotti A, Casertelli GL, Bentivoglio G, Conte N, et al.
970 Endocrine effects of tamoxifen in postmenopausal breast cancer patients. *Tumori*.
971 1984;70(1):61-8. Epub 1984/02/29. PubMed PMID: 6538707.
- 972 109. Hu R, Hilakivi-Clarke L, Clarke R. Molecular mechanisms of tamoxifen-associated
973 endometrial cancer (Review). *Oncol Lett*. 2015;9(4):1495-501. Epub 2015/03/20. doi:
974 10.3892/ol.2015.2962. PubMed PMID: 25788989; PubMed Central PMCID: PMCPMC4356269.
- 975 110. Fleming CA, Heneghan HM, O'Brien D, McCartan DP, McDermott EW, Prichard RS. Meta-
976 analysis of the cumulative risk of endometrial malignancy and systematic review of endometrial
977 surveillance in extended tamoxifen therapy. *British Journal of Surgery*. 2018;105(9):1098-106.
978 doi: 10.1002/bjs.10899.
- 979 111. Berruti A, Terzolo M, Pia A, Angeli A, Dogliotti L. Mitotane associated with etoposide,
980 doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. *Cancer*.
981 1998;83(10):2194-200. doi: [https://doi.org/10.1002/\(SICI\)1097-
982 0142\(19981115\)83:10<2194::AID-CNCR19>3.0.CO;2-3](https://doi.org/10.1002/(SICI)1097-0142(19981115)83:10<2194::AID-CNCR19>3.0.CO;2-3).
- 983 112. Theile D, Haefeli WE, Weiss J. Effects of adrenolytic mitotane on drug elimination
984 pathways assessed in vitro. *Endocrine*. 2015;49(3):842-53. doi: 10.1007/s12020-014-0517-2.

- 985 113. Farland LV, Mu F, Eliassen AH, Hankinson SE, Tworoger SS, Barbieri RL, et al. Menstrual
986 cycle characteristics and steroid hormone, prolactin, and growth factor levels in premenopausal
987 women. *Cancer Causes Control*. 2017;28(12):1441-52. Epub 2017/11/01. doi: 10.1007/s10552-
988 017-0971-2. PubMed PMID: 29086892; PubMed Central PMCID: PMC5718047.
- 989 114. Janda M, Robledo KP, Gebiski V, Armes JE, Alizart M, Cummings M, et al. Complete
990 pathological response following levonorgestrel intrauterine device in clinically stage 1
991 endometrial adenocarcinoma: Results of a randomized clinical trial. *Gynecologic Oncology*.
992 2021;161(1):143-51. doi: <https://doi.org/10.1016/j.ygyno.2021.01.029>.
- 993 115. Barr CE, Ryan NAJ, Derbyshire AE, Wan YL, MacKintosh ML, McVey RJ, et al. Weight Loss
994 During Intrauterine Progestin Treatment for Obesity-associated Atypical Hyperplasia and Early-
995 Stage Cancer of The Endometrium. *Cancer Prev Res (Phila)*. 2021;14(11):1041-50. Epub
996 2021/08/06. doi: 10.1158/1940-6207.Capr-21-0229. PubMed PMID: 34348914.
- 997 116. Lagou V, Mägi R, Hottenga J-J, Grallert H, Perry JRB, Bouatia-Naji N, et al. Sex-dimorphic
998 genetic effects and novel loci for fasting glucose and insulin variability. *Nature Communications*.
999 2021;12(1):24. doi: 10.1038/s41467-020-19366-9.
- 1000 117. Chen J, Spracklen CN, Marenne G, Varshney A, Corbin LJ, Luan Ja, et al. The trans-
1001 ancestral genomic architecture of glycemic traits. *Nature Genetics*. 2021;53(6):840-60. doi:
1002 10.1038/s41588-021-00852-9.
- 1003 118. Larsson SC, Carter P, Vithayathil M, Kar S, Mason AM, Burgess S. Insulin-like growth
1004 factor-1 and site-specific cancers: A Mendelian randomization study. *Cancer Medicine*.
1005 2020;9(18):6836-42. doi: <https://doi.org/10.1002/cam4.3345>.

- 1006 119. Locke AE, Steinberg KM, Chiang CWK, Service SK, Havulinna AS, Stell L, et al. Exome
1007 sequencing of Finnish isolates enhances rare-variant association power. *Nature*.
1008 2019;572(7769):323-8. Epub 2019/07/31. doi: 10.1038/s41586-019-1457-z. PubMed PMID:
1009 31367044.
- 1010 120. Folkersen L, Gustafsson S, Wang Q, Hansen DH, Hedman ÅK, Schork A, et al. Genomic
1011 evaluation of circulating proteins for drug target characterisation and precision medicine.
1012 bioRxiv. 2020:2020.04.03.023804. doi: 10.1101/2020.04.03.023804.
- 1013 121. C Reactive Protein Coronary Heart Disease Genetics Collaboration (CCGC). Association
1014 between C reactive protein and coronary heart disease: mendelian randomisation analysis
1015 based on individual participant data. *BMJ*. 2011;342:d548. doi: 10.1136/bmj.d548.
- 1016

1017 **Figure Legends:**

1018 **Fig 1. Flowchart detailing the process of identifying previously reported risk factors with suitable**
1019 **genetic instruments.**

1020 TNF- α = tumour necrosis factor- α , IGFBP-1 = insulin-like growth factor-binding protein-1, LDL = low-
1021 density lipoprotein, HDL = high-density lipoprotein, IGF-1 = insulin-like growth factor-1, IL-6 =
1022 interleukin-6, CRP = C-reactive protein, SHBG = sex hormone-binding globulin.

1023

1024 **Fig 2. DAG demonstrating the core assumptions of Mendelian randomization.**

1025 DAG = directed acyclic diagram, G = genetic instrument, E = exposure, O = outcome, C = confounding
1026 factors. Arrows labelled 1, 2, and 3 represent the three core assumptions of MR: (1) the instrument
1027 strongly associates with the exposure (“relevance”); (2) there is no confounding of the instrument-
1028 outcome relationship (“exchangeability”); and (3) the instrument only affects the outcome through the
1029 exposure (“exclusion restriction”). MR uses genetic instruments to proxy exposures in order to
1030 strengthen causal inference in observational epidemiological settings. As these genetic instruments are
1031 randomly inherited at meiosis, they should not be affected by conventional confounding factors like
1032 environmental, lifestyle, and behavioural traits. In addition, since germline genetic variants are fixed at
1033 conception and cannot be altered by subsequent exposures, they are not susceptible to reverse
1034 causation. Finally, germline genotype can be measured relatively precisely using modern genotyping
1035 technologies which minimises measurement error. Collectively, these properties of germline genetic
1036 variants (along with technologies that measure them) permit MR analyses to minimise many of the
1037 sources of bias which can undermine robust causal inference in conventional observational
1038 epidemiological analyses.

1039

1040

1041 **Fig 3. DAG demonstrating the proposed causal interactions of BMI, SHBG, fasting insulin, and**
1042 **bioavailable testosterone on endometrial cancer (overall and the endometrioid histological subtype).**

1043 DAG = directed acyclic diagram, BMI = body mass index, SHBG = sex hormone-binding globulin.

1044

1045 **Fig 4. Mendelian randomization analysis of BMI on overall and subtype-specific endometrial cancer**
1046 **risk.**

1047 Results of MR analyses examining the effect of adult BMI on risk of overall and subtype-specific
1048 endometrial cancer risk.

1049

1050 **Fig 5. Mendelian randomization analysis of total serum cholesterol, fasting insulin, total testosterone,**
1051 **bioavailable testosterone, and sex hormone-binding globulin (SHBG) on overall and endometrioid**
1052 **endometrial cancer risk.**

1053 LDL = low-density lipoprotein, HDL = high-density lipoprotein, IGF-1 = insulin-like growth factor-1, IL-6 =
1054 interleukin-6, CRP = C-reactive protein, SHBG = sex hormone-binding globulin. (A) Results of MR analyses
1055 examining the effects of previously reported molecular risk factors on risk of overall endometrial cancer
1056 risk. (B) Results of MR analyses examining the effects of previously reported molecular risk factors on
1057 risk of endometrioid subtype endometrial cancer risk.

1058

1059 **Fig 6. Mendelian randomization analysis of adult BMI on previously reported endometrial cancer risk**
1060 **factors.**

1061 SHBG = sex hormone-binding globulin, LDL = low-density lipoprotein, CRP = C-reactive protein.

1062 **Table 1. Details of the instruments used for exposures.**

Exposure	GWAS	Sample size	Number of SNPs	R ²	F-statistic	Sex-specificity
Adult BMI	Yengo et al. [42]	681,275	507	0.078	57,847	Combined
LDL-cholesterol	Willer et al. [34]	188,577	81	0.182	15,002	Combined
HDL-cholesterol	Willer et al. [34]	188,577	89	0.055	10,978	Combined
Triglyceride	Willer et al. [34]	188,577	55	0.052	9,811	Combined
Total serum cholesterol	Willer et al. [34]	188,577	88	0.063	12,696	Combined
Glucose	Neale et al. [36]	361,194	109	0.036	11,776	Female
Fasting insulin (unadjusted for BMI)	Lagou et al. [116]	98,210	14	0.005	523	Combined
Fasting insulin (adjusted for BMI)	Chen et al. [117]	150,571	14	0.006	865	Combined
IGF-1 (cis and trans variants)	Sinnott-Armstrong et al. [37]	358,072	413	0.036	13,367	Combined
IGF-1 (cis variants)	Larsson et al. [118]	358,072	1	0.002	814	Combined

IL-6	Georgakis et al. [38]	204,402	7	0.004	911	Combined
Adiponectin (cis and trans variants)	Locke et al. [119]	14,172	3	0.023	328	Combined
Adiponectin (cis variants)	Locke et al. [119]	14,172	3	0.023	334	Combined
Leptin	Folkersen et al. [120]	30,931	1	0.001	34	Combined
CRP (cis and trans variants)	Ligthart et al. [41]	204,402	45	0.035	7,414	Combined
CRP (cis variants)	C Reactive Protein Coronary Heart Disease Genetics Collaboration (CCGC) [121]	105,476	4	0.010	1,030	Combined
Total testosterone	Ruth et al. [29]	230,454	131	0.052	10,103	Female
Bioavailable testosterone	Ruth et al. [29]	188,507	147	0.054	10,599	Female

SHBG	Ruth et al. [29]	189,473	215	0.122	26,286	Female
------	------------------	---------	-----	-------	--------	--------

1063 BMI is scaled to an SD increase (4.7 kg/m²). For the analysis involving the plasma proteome, due to the
1064 requirement of increased statistical power in order to overcome the multiple testing burden, alternative
1065 summary genetic association data for BMI were obtained from a genome-wide association study of
1066 681,275 individuals of European ancestry (note that this summary genetic data could not be used for
1067 other analyses due to substantial overlap of participants with summary genetic data of other traits) [42].
1068 The CRP GWAS included some individuals of non-European ancestry and adjusted for ancestry where
1069 applicable. BMI = body mass index, LDL = low-density lipoprotein, HDL = high density lipoprotein, IGF-1 =
1070 Insulin-like growth factor-1, IL-6 = interleukin-6, CRP = C-reactive protein, SHBG = sex hormone-binding
1071 globulin, LD = linkage disequilibrium. For instrument construction of IGF-1 (cis and trans variants), a *P*
1072 value of 5 x 10⁻⁶ was used.

1073 **Table 2. Results of MR analyses examining the effect of adult BMI on risk of overall and subtype-**
 1074 **specific endometrial cancer risk**

Outcome	Method	OR (95% CI)	P value
Overall	IVW	1.88 (1.69 to 2.09)	3.87 x 10 ⁻³¹
endometrial cancer	Weighted median	1.89 (1.58 to 2.26)	5.18 x 10 ⁻¹²
	Weighted mode	1.82 (1.35 to 2.44)	9.88 x 10 ⁻⁵
	MR Egger	2.03 (1.54 to 2.67)	8.41 x 10 ⁻⁷
Endometrioid endometrial cancer	IVW	1.89 (1.65 to 2.16)	1.67 x 10 ⁻²⁰
	Weighted median	1.99 (1.60 to 2.46)	3.24 x 10 ⁻¹⁰
	Weighted mode	1.96 (1.42 to 2.69)	4.67 x 10 ⁻⁵
Non-endometrioid endometrial cancer	MR Egger	2.15 (1.52 to 3.03)	1.74 x 10 ⁻⁵
	IVW	1.67 (1.19 to 2.35)	3.03 x 10 ⁻³
	Weighted median	2.29 (1.24 to 4.22)	8.24 x 10 ⁻³
cancer	Weighted mode	1.89 (0.77 to 4.63)	1.63 x 10 ⁻¹
	MR Egger	2.25 (0.99 to 5.07)	5.28 x 10 ⁻²

1075 ORs are shown per increase in SD (4.7 kg/m²) BMI. BMI = body mass index, IVW = inverse-variance
 1076 weighted.

1077

1078 **Table 3. Results of MR analyses examining the effect of previously reported and novel potential**
 1079 **molecular risk factors and overall and endometrioid subtype endometrial cancer risk.**

Exposure	Outcome	Method	OR (95% CI)	P value
LDL- cholesterol	Overall endometrial cancer	IVW	0.95 (0.87 to 1.04)	3.05 x 10 ⁻¹
		Weighted median	0.92 (0.82 to 1.03)	1.31 x 10 ⁻¹
		Weighted mode	0.91 (0.82 to 1.02)	9.54 x 10 ⁻²
	Endometrioid endometrial cancer	MR Egger	0.90 (0.79 to 1.03)	1.35 x 10 ⁻¹
		IVW	0.98 (0.89 to 1.08)	6.70 x 10 ⁻¹
		Weighted median	0.96 (0.84 to 1.10)	5.61 x 10 ⁻¹
		Weighted mode	0.93 (0.83 to 1.06)	2.79 x 10 ⁻¹
		MR Egger	0.93 (0.81 to 1.07)	3.31 x 10 ⁻¹
HDL- cholesterol	Overall endometrial cancer	IVW	1.09 (0.97 to 1.23)	1.48 x 10 ⁻¹
		Weighted median	1.10 (0.96 to 1.26)	1.89 x 10 ⁻¹
		Weighted mode	1.07 (0.94 to 1.23)	3.11 x 10 ⁻¹
	Endometrioid endometrial cancer	MR Egger	1.08 (0.86 to 1.35)	4.99 x 10 ⁻¹
		IVW	1.04 (0.90 to 1.19)	6.05 x 10 ⁻¹
		Weighted median	0.99 (0.84 to 1.16)	8.76 x 10 ⁻¹
		Weighted mode	1.03 (0.88 to 1.21)	7.23 x 10 ⁻¹
		MR Egger	0.92 (0.71 to 1.20)	5.61 x 10 ⁻¹
Triglyceride	Overall endometrial cancer	IVW	0.95 (0.84 to 1.06)	3.55 x 10 ⁻¹
		Weighted median	0.87 (0.75 to 1.01)	7.75 x 10 ⁻²
		Weighted mode	0.91 (0.79 to 1.04)	1.61 x 10 ⁻¹
		MR Egger	0.83 (0.69 to 1.00)	6.03 x 10 ⁻²
	Endometrioid endometrial cancer	IVW	0.95 (0.83 to 1.09)	4.65 x 10 ⁻¹

		Weighted median	0.92 (0.78 to 1.08)	3.21×10^{-1}
		Weighted mode	0.91 (0.77 to 1.08)	2.87×10^{-1}
		MR Egger	0.87 (0.70 to 1.07)	2.02×10^{-1}
Total serum	Overall endometrial cancer	IVW	0.90 (0.81 to 1.00)	4.01×10^{-2}
cholesterol		Weighted median	0.80 (0.71 to 0.90)	2.08×10^{-4}
		Weighted mode	0.82 (0.73 to 0.91)	5.97×10^{-4}
		MR Egger	0.84 (0.71 to 0.98)	3.09×10^{-2}
	Endometrioid endometrial cancer	IVW	0.91 (0.82 to 1.02)	9.31×10^{-2}
		Weighted median	0.81 (0.71 to 0.93)	3.40×10^{-3}
		Weighted mode	0.84 (0.74 to 0.97)	1.64×10^{-2}
		MR Egger	0.86 (0.72 to 1.01)	7.60×10^{-2}
Glucose	Overall endometrial cancer	IVW	0.95 (0.79 to 1.14)	5.64×10^{-1}
		Weighted median	0.97 (0.80 to 1.17)	7.36×10^{-1}
		Weighted mode	0.93 (0.78 to 1.11)	4.47×10^{-1}
		MR Egger	0.99 (0.73 to 1.34)	9.29×10^{-1}
	Endometrioid endometrial cancer	IVW	0.90 (0.73 to 1.11)	3.26×10^{-1}
		Weighted median	0.98 (0.77 to 1.23)	8.31×10^{-1}
		Weighted mode	0.98 (0.80 to 1.20)	8.29×10^{-1}
		MR Egger	0.94 (0.67 to 1.33)	7.39×10^{-1}
Fasting	Overall endometrial cancer	IVW	3.93 (2.29 to 6.74)	7.18×10^{-7}
insulin		Weighted median	3.49 (1.60 to 7.62)	1.67×10^{-3}
		Weighted mode	3.55 (0.85 to 14.78)	1.06×10^{-1}
		MR Egger	8.28 (0.67 to 102.10)	1.25×10^{-1}
	Endometrioid endometrial cancer	IVW	4.64 (2.30 to 9.36)	1.84×10^{-5}

		Weighted median	3.93 (1.56 to 9.93)	3.80×10^{-3}
		Weighted mode	3.28 (0.69 to 15.62)	1.61×10^{-1}
		MR Egger	21.59 (0.78 to 593.93)	9.66×10^{-2}
IGF-1 (cis and trans variants)	Overall endometrial cancer	IVW	0.93 (0.85 to 1.06)	2.60×10^{-1}
		Weighted median	1.01 (0.85 to 1.20)	8.96×10^{-1}
		Weighted mode	1.22 (0.89 to 1.67)	2.28×10^{-1}
		MR Egger	1.17 (0.85 to 1.60)	3.49×10^{-1}
	Endometrioid endometrial cancer	IVW	0.89 (0.77 to 1.03)	1.12×10^{-1}
		Weighted median	1.03 (0.84 to 1.25)	8.06×10^{-1}
		Weighted mode	1.32 (0.92 to 1.90)	1.30×10^{-1}
		MR Egger	1.22 (0.85 to 1.76)	2.75×10^{-1}
IGF-1 (cis variants)	Overall endometrial cancer	Wald ratio	1.20 (0.79 to 1.82)	3.92×10^{-1}
	Endometrioid endometrial cancer	Wald ratio	1.40 (0.85 to 2.28)	1.84×10^{-1}
IL-6 (scaled to natural log transformed mg/L change in CRP)	Overall endometrial cancer	IVW	0.90 (0.66 to 1.21)	4.80×10^{-1}
	Endometrioid endometrial cancer	IVW	0.86 (0.60 to 1.23)	4.01×10^{-1}
Adiponectin (cis and trans variants)	Overall endometrial cancer	IVW	0.92 (0.79 to 1.08)	3.17×10^{-1}
	Endometrioid endometrial cancer	IVW	0.94 (0.78 to 1.13)	4.99×10^{-1}
Adiponectin (cis variants)	Overall endometrial cancer	IVW	0.95 (0.83 to 1.08)	3.94×10^{-1}
	Endometrioid endometrial cancer	IVW	1.00 (0.86 to 1.16)	9.92×10^{-1}
Leptin	Overall endometrial cancer	Wald Ratio	1.03 (0.68 to 1.54)	8.96×10^{-1}

	Endometrioid endometrial cancer	Wald Ratio	0.88 (0.54 to 1.42)	5.99×10^{-1}
CRP (cis and trans variants)	Overall endometrial cancer	IVW	1.07 (0.94 to 1.22)	3.03×10^{-1}
		Weighted median	0.97 (0.84 to 1.12)	6.76×10^{-1}
		Weighted mode	1.02 (0.91 to 1.14)	7.80×10^{-1}
		MR Egger	0.96 (0.80 to 1.16)	6.99×10^{-1}
	Endometrioid endometrial cancer	IVW	1.12 (0.96 to 1.30)	1.39×10^{-1}
		Weighted median	1.03 (0.87 to 1.23)	6.92×10^{-1}
		Weighted mode	1.04 (0.90 to 1.20)	6.34×10^{-1}
		MR Egger	0.97 (0.78 to 1.20)	7.69×10^{-1}
CRP (cis variants)	Overall endometrial cancer	IVW	0.98 (0.85 to 1.13)	7.52×10^{-1}
	Endometrioid endometrial cancer	IVW	0.98 (0.83 to 1.16)	8.02×10^{-1}
Total testosterone	Overall endometrial cancer	IVW	1.64 (1.43 to 1.88)	1.71×10^{-12}
		Weighted median	1.67 (1.39 to 2.01)	3.95×10^{-8}
		Weighted mode	1.74 (1.38 to 2.20)	8.33×10^{-6}
	Endometrioid endometrial cancer	MR Egger	1.81 (1.38 to 2.38)	4.17×10^{-5}
		IVW	1.60 (1.36 to 1.87)	8.70×10^{-9}
		Weighted median	1.81 (1.45 to 2.26)	2.05×10^{-7}
		Weighted mode	1.88 (1.42 to 2.48)	2.34×10^{-5}
Bioavailable testosterone	Overall endometrial cancer	MR Egger	1.74 (1.26 to 2.41)	1.02×10^{-3}
		IVW	1.46 (1.29 to 1.65)	3.48×10^{-9}
		Weighted median	1.47 (1.20 to 1.82)	2.46×10^{-4}
		Weighted mode	1.51 (1.19 to 1.93)	1.16×10^{-3}
	Endometrioid endometrial cancer	MR Egger	1.90 (1.46 to 2.47)	5.63×10^{-6}
		IVW	1.46 (1.26 to 1.69)	3.08×10^{-7}

		Weighted median	1.42 (1.14 to 1.76)	1.97×10^{-3}
		Weighted mode	1.60 (1.20 to 2.13)	1.59×10^{-3}
		MR Egger	1.79 (1.31 to 2.43)	3.08×10^{-7}
SHBG	Overall endometrial cancer	IVW	0.71 (0.59 to 0.85)	2.07×10^{-4}
		Weighted median	0.64 (0.48 to 0.86)	2.54×10^{-3}
		Weighted mode	0.69 (0.53 to 0.89)	4.97×10^{-3}
		MR Egger	0.62 (0.46 to 0.84)	2.52×10^{-3}
	Endometrioid endometrial cancer	IVW	0.65 (0.54 to 0.80)	3.31×10^{-5}
		Weighted median	0.60 (0.43 to 0.86)	4.90×10^{-3}
		Weighted mode	0.58 (0.40 to 0.82)	2.50×10^{-3}
		MR Egger	0.61 (0.44 to 0.84)	3.33×10^{-3}

1080 ORs are shown per increase in inverse normal transformed nmol/L SHBG, natural log transformed
 1081 pmol/L fasting insulin, inverse normal transformed nmol/L total testosterone, inverse normal
 1082 transformed nmol/L bioavailable testosterone, SD (38.7 mg/dL) LDL-cholesterol, nmol/L IGF-1, mmol/L
 1083 blood glucose, natural log transformed CRP mg/L IL-6, natural log transformed ug/ml adiponectin for
 1084 combined instrument, natural log transformed ug/ml cis-only adiponectin, natural log transformed mg/L
 1085 CRP, mg/dL triglyceride, SD (41.7 mg/dL) total serum cholesterol, mg/dL HDL-cholesterol, pg/mL leptin.
 1086 LDL = low-density lipoprotein, HDL = high density lipoprotein, IGF-1 = Insulin-like growth factor-1, IL-6 =
 1087 interleukin-6, CRP = C-reactive protein, SHBG = sex hormone-binding globulin, IVW = inverse-variance
 1088 weighted. For instrument construction of IGF-1 (cis and trans variants), a P value of 5×10^{-6} was used.

1089

1090 **Table 4. Results of MR analyses examining the effect of BMI on previously reported molecular risk**
 1091 **factors.**

Outcome	Method	Effect estimate (95% CI)	P value
Total serum cholesterol	IVW	-0.03 (-0.06 to 0.01)	1.22×10^{-1}
	Weighted median	-0.06 (-0.11 to -0.01)	2.98×10^{-2}
	Weighted mode	-0.08 (-0.15 to 0.00)	4.46×10^{-2}
	MR Egger	-0.08 (-0.16 to 0.00)	3.89×10^{-2}
Fasting insulin	IVW	0.17 (0.15 to 0.19)	1.51×10^{-74}
	Weighted median	0.18 (0.15 to 0.21)	8.51×10^{-31}
	Weighted mode	0.18 (0.12 to 0.24)	1.88×10^{-9}
	MR Egger	0.20 (0.16 to 0.25)	1.30×10^{-16}
Total testosterone	IVW	0.08 (0.05 to 0.11)	9.04×10^{-10}
	Weighted median	0.06 (0.03 to 0.09)	4.95×10^{-4}
	Weighted mode	-0.01 (-0.08 to 0.07)	8.60×10^{-1}
	MR Egger	0.02 (-0.05 to 0.09)	5.23×10^{-1}
Bioavailable testosterone	IVW	0.26 (0.23 to 0.29)	9.97×10^{-68}
	Weighted median	0.24 (0.20 to 0.28)	1.72×10^{-38}
	Weighted mode	0.09 (0.01 to 0.17)	2.41×10^{-2}
	MR Egger	0.16 (0.08 to 0.24)	4.36×10^{-5}
SHBG	IVW	-0.17 (-0.19 to -0.16)	4.86×10^{-125}
	Weighted median	-0.16 (-0.18 to -0.15)	8.85×10^{-77}
	Weighted mode	-0.15 (-0.18 to -0.12)	8.43×10^{-20}
	MR Egger	-0.13 (-0.17 to -0.09)	3.11×10^{-11}

1092 BMI is scaled to an SD increase (4.7 kg/m^2). Effect estimate represents change in SD (41.7 mg/dL) total
1093 serum cholesterol, natural log transformed pmol/L fasting insulin, inverse normal transformed nmol/L
1094 total testosterone, inverse normal transformed nmol/L bioavailable testosterone, and inverse normal
1095 transformed nmol/L SHBG. SHBG = sex hormone-binding globulin, IVW = inverse-variance weighted.

1096 **Table 5. Results of multivariable MR mediation analysis examining the effect of BMI and endometrial**
 1097 **cancer with previously reported molecular risk factors as potential mediators.**

Mediator	Outcome	Direct Effect of BMI on Outcome	Indirect Effect of Mediator on Outcome	% Mediated (95% CI)	P value
Fasting insulin	Overall	1.75	1.07	11% (1 to 21%)	2.89 x 10 ⁻²
	Endometrial Cancer				
	Endometrioid	1.72	1.11	16% (3 to 28%)	1.24 x 10 ⁻²
	Endometrial Cancer				
Bioavailable testosterone	Overall	1.70	1.11	15% (10 to 20%)	1.43 x 10 ⁻⁸
	Endometrial Cancer				
	Endometrioid	1.72	1.11	15% (9 to 22%)	2.15 x 10 ⁻⁶
	Endometrial Cancer				
SHBG	Overall	1.80	1.04	7% (1 to 12%)	1.81 x 10 ⁻²
	Endometrial Cancer				
	Endometrioid	1.86	1.02	2% (-9 to 14%)	6.87 x 10 ⁻¹
	Endometrial Cancer				

1098 Direct effect is defined as the remaining effect of the exposure (BMI) on the outcome (endometrial
 1099 cancer risk) when the effect of the candidate mediator on the outcome has been adjusted for. Indirect
 1100 effect is defined as the effect of the exposure (BMI) on the outcome (endometrial cancer risk) through
 1101 the candidate mediator. SHBG = sex hormone-binding globulin.

1102 **Supporting Information Captions**

1103 **S1 Appendix. List of unique molecular traits identified from literature search.**

1104 **S2 Appendix. Supplementary methods.**

1105 **S3 Appendix. PubMed search terms for literature review.**

1106 **S4 Table. Additional information on GWAS, including covariates adjusted for.**

1107 **S5 Table. Sample overlap between GWAS.**

1108 **S6 Table. Conditional F-statistics for multivariable Mendelian randomization of BMI and mediators on**
1109 **endometrial cancer risk.**

1110 **S7 Figure. Leave-one-out analysis for MR examining the effect of adult BMI on overall endometrial**
1111 **cancer risk.**

1112 **S8 Table. Results of female BMI sensitivity analysis MR.**

1113 **S9 Table. Results from sensitivity analyses examining the influence of Winner's curse on GWAS with**
1114 **overlapping samples.**

1115 **S10 Figure. Leave-one-out analysis for MR examining the effect of adult BMI on endometrioid**
1116 **endometrial cancer risk.**

1117 **S11 Figure. Leave-one-out analysis for MR examining the effect of adult BMI on non-endometrioid**
1118 **endometrial cancer risk.**

1119 **S12 Figure. Leave-one-out analysis for MR examining the effect of total testosterone level on**
1120 **endometrial cancer risk.**

1121 **S13 Figure. Leave-one-out analysis for MR examining the effect of bioavailable testosterone level on**
1122 **endometrial cancer risk.**

1123 **S14 Figure. Leave-one-out analysis for MR examining the effect of fasting insulin level on endometrial**
1124 **cancer risk.**

1125 **S15 Figure. Leave-one-out analysis for MR examining the effect of SHBG level on endometrial cancer**
1126 **risk.**

1127 **S16 Figure. Leave-one-out analysis for MR examining the effect of total serum cholesterol level on**
1128 **endometrial cancer risk.**

1129 **S17 Table. Results of female-specific SNP fasting insulin sensitivity analysis MR.**

1130 **S18 Table. Results of female-specific SNP CRP sensitivity analysis MR.**

1131 **S19 Figure. Leave-one-out analysis for MR examining the effect of total testosterone level on**
1132 **endometrioid endometrial cancer risk.**

1133 **S20 Figure. Leave-one-out analysis for MR examining the effect of bioavailable testosterone level on**
1134 **endometrioid endometrial cancer risk.**

1135 **S21 Figure. Leave-one-out analysis for MR examining the effect of fasting insulin level on**
1136 **endometrioid endometrial cancer risk.**

1137 **S22 Figure. Leave-one-out analysis for MR examining the effect of SHBG level on endometrioid**
1138 **endometrial cancer risk.**

1139 **S23 Figure. Leave-one-out analysis for MR examining the effect of adult BMI on fasting insulin level.**

- 1140 **S24 Figure. Leave-one-out analysis for MR examining the effect of adult BMI on SHBG level.**
- 1141 **S25 Figure. Leave-one-out analysis for MR examining the effect of adult BMI on bioavailable**
1142 **testosterone level.**
- 1143 **S26 Figure. Leave-one-out analysis for MR examining the effect of adult BMI on total serum**
1144 **cholesterol level.**
- 1145 **S27 Figure. Leave-one-out analysis for MR examining the effect of adult BMI on C-reactive protein**
1146 **level.**
- 1147 **S28 Table. Results of female-specific SNP BMI sensitivity mediation analysis.**
- 1148 **S29 Table. Results of female-specific SNP fasting insulin mediation analysis.**
- 1149 **S30 Table. Results of multivariable MR mediation analysis examining the effect of BMI and**
1150 **endometrial cancer with fasting insulin as a potential mediator with BMI-adjusted fasting insulin**
1151 **instrument and 100 SNPs from BMI instrument.**
- 1152 **S31 Table. Results from sensitivity analyses examining the influence of Winner's curse on GWAS with**
1153 **overlapping samples in analyses determining the mediating role of traits in the relationship between**
1154 **BMI and endometrial cancer risk.**
- 1155 **S32 Table. Results from sensitivity analyses examining the influence of Winner's curse on GWAS with**
1156 **overlapping samples in analyses determining the interdependent effects of mediators of the**
1157 **relationship between BMI and endometrial cancer risk.**
- 1158 **S33 Table. Conditional F-statistics for further multivariable Mendelian randomization analyses.**
- 1159 **S34 Table. Results of multivariable MR mediation analysis examining the effect of endometrial cancer**
1160 **with pairs of confirmed mediating molecular traits without BMI.**

1161 **S35 Table. Results of multivariable MR mediation analysis examining the effect of BMI and**
1162 **endometrial cancer with fasting insulin as a potential mediator with 100 SNPs from BMI instrument.**

1163 **S36 Table. Results of multivariable MR mediation analysis examining the effect of BMI and**
1164 **endometrial cancer with fasting insulin as a potential mediator with BMI-adjusted fasting insulin**
1165 **instrument.**

1166 **S37 Table. Conditional F-statistics for fasting insulin (adjusted for BMI) and BMI with differing**
1167 **thresholds used to construct fasting insulin.**

1168 **S38 Table. Results of multivariable MR mediation analysis examining the effect of BMI and**
1169 **endometrial cancer with all confirmed mediating molecular traits with BMI-adjusted fasting insulin.**

1170 **S39 Table. Results of multivariable MR mediation analysis examining the effect of BMI and**
1171 **endometrial cancer with pairs of confirmed mediating molecular traits.**

1172 **S40 Table. Results of multivariable MR mediation analysis examining the effect of BMI and**
1173 **endometrial cancer with all confirmed mediating molecular traits including fasting insulin adjusted for**
1174 **BMI with 100 SNPs from BMI instrument.**

1175 **S41 Table. Results of multivariable MR mediation analysis examining the effect of BMI and**
1176 **endometrial cancer with pairs of confirmed mediating molecular traits with 100 SNPs from BMI**
1177 **instrument.**

1178 **S42 Table. Results of multivariable MR mediation analysis examining the effect of endometrial cancer**
1179 **with all confirmed mediating molecular traits without BMI.**

1180 **S43 Table. Results of sensitivity analysis examining the effect of only including 100 SNPs for the BMI**
1181 **instrument in MR analyses.**

- 1182 **S44 Table. Conditional F-statistics with different levels of genetic correlation for SHBG and BMI in**
1183 **multivariable Mendelian randomization analyses.**
- 1184 **S45 Table. Results of HEIDI test-filtered low-density lipoprotein (LDL) cholesterol and overall**
1185 **endometrial cancer MR.**

20 risk factors identified from
two PubMed literature searches



5 risk factors excluded due to no
GWAS available with any SNPs at
genome-wide significance

($P < 5 \times 10^{-8}$)

*30-minute postchallenge insulin,
TNF- α , visfatin, progesterone,
IGFBP-1*

1 risk factor excluded due to
inappropriate instrument, as
demonstrated by Steiger filtering
Oestradiol

14 risk factors investigated in
MR analyses
*LDL-cholesterol, HDL-cholesterol,
triglyceride, total serum
cholesterol, glucose, fasting
insulin, IGF-1, IL-6, adiponectin,
leptin, CRP, total testosterone,
bioavailable testosterone, SHBG*

Fig 1.




Fig 2.




Fig 3.




Fig 4.




Fig 5.




Fig 6.